https://trial.medpath.com/news/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted 2024-10-25T09:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted 2024-10-25T09:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/aquestive-therapeutics-announces-positive-topline-results-from-oral-allergy-syndrome 2024-10-25T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aquestive-therapeutics-announces-positive-topline-results-from-oral-allergy-syndrome 2024-10-25T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/intermittent-versus-continuous-calorie-restriction-for-treatment-of-metabolic-dysfunction-pubmed 2024-10-25T08:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intermittent-versus-continuous-calorie-restriction-for-treatment-of-metabolic-dysfunction-pubmed 2024-10-25T08:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/dexcom-submits-15-day-cgm-to-fda-stock-sinks-after-hours-despite-street-beating-q3 2024-10-25T08:29:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dexcom-submits-15-day-cgm-to-fda-stock-sinks-after-hours-despite-street-beating-q3 2024-10-25T08:29:36+00:00 weekly 0.7 https://trial.medpath.com/news/reporting-clinical-trial-results-to-the-market-taylor-wessing 2024-10-25T08:21:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reporting-clinical-trial-results-to-the-market-taylor-wessing 2024-10-25T08:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/multidisciplinary-collaboration-and-biomarker-testing-reshape-early-stage-lung-cancer-care 2024-10-25T08:15:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multidisciplinary-collaboration-and-biomarker-testing-reshape-early-stage-lung-cancer-care 2024-10-25T08:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-donanemab-could-bring-new-hope-to-alzheimer-s-patients-in-australia-following 2024-10-25T08:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-donanemab-could-bring-new-hope-to-alzheimer-s-patients-in-australia-following 2024-10-25T08:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/founder-of-hua-medicine-dr-chen-li-was-awarded-the-c-c-tan-life-science 2024-10-25T08:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/founder-of-hua-medicine-dr-chen-li-was-awarded-the-c-c-tan-life-science 2024-10-25T08:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/multi-center-study-validates-safety-and-efficacy-of-senhance-robotic-system-in-colorectal-surgery 2024-10-25T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multi-center-study-validates-safety-and-efficacy-of-senhance-robotic-system-in-colorectal-surgery 2024-10-25T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-create-cancer-patients-digital-twins-to-predict-how-well-treatments-may-work 2024-10-25T07:48:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-create-cancer-patients-digital-twins-to-predict-how-well-treatments-may-work 2024-10-25T07:48:27+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sanofi-q3-15-7-sales-growth-boosted-by-earlier-than-anticipated-vaccine-sales 2024-10-25T07:45:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sanofi-q3-15-7-sales-growth-boosted-by-earlier-than-anticipated-vaccine-sales 2024-10-25T07:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients 2024-10-25T07:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients 2024-10-25T07:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/clarametyx-biosciences-initiates-phase-2a-trial-for-cmtx-101-in-cystic-fibrosis-patients 2024-10-25T07:12:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarametyx-biosciences-initiates-phase-2a-trial-for-cmtx-101-in-cystic-fibrosis-patients 2024-10-25T07:12:37+00:00 weekly 0.7 https://trial.medpath.com/news/miami-cancer-institute-launches-innovative-app-fellowship-for-hematology-and-bone-marrow-transplant-care 2024-10-25T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miami-cancer-institute-launches-innovative-app-fellowship-for-hematology-and-bone-marrow-transplant-care 2024-10-25T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promising-phase-ii-results-and-market-potential-support-buy-rating-for-intellia-therapeutics 2024-10-25T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-phase-ii-results-and-market-potential-support-buy-rating-for-intellia-therapeutics 2024-10-25T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/news/olanzapine-and-cannabis-can-help-manage-nausea-during-chemotherapy 2024-10-25T06:46:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olanzapine-and-cannabis-can-help-manage-nausea-during-chemotherapy 2024-10-25T06:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-sanofi-announce-presentation-of-dupixent-phase-3-data-in-csu 2024-10-25T05:59:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-sanofi-announce-presentation-of-dupixent-phase-3-data-in-csu 2024-10-25T05:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/stripe-initiative-advances-pharmacogenetic-testing-standards-with-focus-on-dpyd-guided-chemotherapy 2024-10-25T05:54:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stripe-initiative-advances-pharmacogenetic-testing-standards-with-focus-on-dpyd-guided-chemotherapy 2024-10-25T05:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-second-alzheimer-s-drug-but-opportunity-remains-for-decision-change-says-globaldata 2024-10-25T04:31:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-rejects-second-alzheimer-s-drug-but-opportunity-remains-for-decision-change-says-globaldata 2024-10-25T04:31:09+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-kicks-off-new-trial-aiming-to-improve-heart-failure-outcomes-with-cardiomems-heartmate-3 2024-10-25T03:32:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-kicks-off-new-trial-aiming-to-improve-heart-failure-outcomes-with-cardiomems-heartmate-3 2024-10-25T03:32:36+00:00 weekly 0.7 https://trial.medpath.com/news/cultural-adaptation-and-flexibility-key-to-improving-diversity-in-diabetes-clinical-trials 2024-10-25T03:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cultural-adaptation-and-flexibility-key-to-improving-diversity-in-diabetes-clinical-trials 2024-10-25T03:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/cotton-o-neil-marks-20-years-of-focused-clinical-research-program-wibw 2024-10-25T03:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cotton-o-neil-marks-20-years-of-focused-clinical-research-program-wibw 2024-10-25T03:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-gets-fda-approval-for-affera-technology-morningstar 2024-10-25T03:14:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-gets-fda-approval-for-affera-technology-morningstar 2024-10-25T03:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/duchenne-muscular-dystrophy-dmd-pipeline-analysis-2024-openpr-com 2024-10-25T03:06:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duchenne-muscular-dystrophy-dmd-pipeline-analysis-2024-openpr-com 2024-10-25T03:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ribociclib-kisqali-r-recognized-as-category-1-preferred-breast-cancer-adjuvant 2024-10-25T02:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-ribociclib-kisqali-r-recognized-as-category-1-preferred-breast-cancer-adjuvant 2024-10-25T02:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/digital-twin-could-help-predict-how-well-cancer-treatments-may-work-scimex 2024-10-25T01:20:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-twin-could-help-predict-how-well-cancer-treatments-may-work-scimex 2024-10-25T01:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/naya-biosciences-announces-initiation-of-phase-1-2a-globenewswire 2024-10-25T01:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naya-biosciences-announces-initiation-of-phase-1-2a-globenewswire 2024-10-25T01:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-launches-clinical-trial-to-optimize-heart-failure-treatment-hit-consultant 2024-10-25T00:56:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-launches-clinical-trial-to-optimize-heart-failure-treatment-hit-consultant 2024-10-25T00:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/the-impact-of-fdora-on-clinical-trial-diversity 2024-10-25T00:35:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-impact-of-fdora-on-clinical-trial-diversity 2024-10-25T00:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/everest-medicines-announces-the-launch-of-velsipity-r-in-the-guangdong-hong-kong 2024-10-25T00:28:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/everest-medicines-announces-the-launch-of-velsipity-r-in-the-guangdong-hong-kong 2024-10-25T00:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/metsera-reports-highly-competitive-results-from-ongoing-biospace 2024-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metsera-reports-highly-competitive-results-from-ongoing-biospace 2024-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-test-engineered-skin-for-severe-burns-starts-in-melbourne-s-alfred-hospital 2024-10-24T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-test-engineered-skin-for-severe-burns-starts-in-melbourne-s-alfred-hospital 2024-10-24T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for-treatment-of-c3-glomerulopathy 2024-10-24T23:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for-treatment-of-c3-glomerulopathy 2024-10-24T23:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-ribociclib-revamps-hr-her2-breast-cancer-management-onclive 2024-10-24T23:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-ribociclib-revamps-hr-her2-breast-cancer-management-onclive 2024-10-24T23:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/dr-ma-on-interim-efficacy-and-safety-data-with-rly-2608-in-pi3ka-mutant-hr-her2 2024-10-24T23:02:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-ma-on-interim-efficacy-and-safety-data-with-rly-2608-in-pi3ka-mutant-hr-her2 2024-10-24T23:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/sbrt-vs-conventional-radiotherapy-for-localized-prostate-cancer-the-asco-post 2024-10-24T22:49:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sbrt-vs-conventional-radiotherapy-for-localized-prostate-cancer-the-asco-post 2024-10-24T22:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-moves-into-phase-iii-with-ntla-2002-but-concerns-remain-scrip 2024-10-24T22:03:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-moves-into-phase-iii-with-ntla-2002-but-concerns-remain-scrip 2024-10-24T22:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-medtronic-s-affera-sphere-9-for-cardiac-ablation-massdevice 2024-10-24T21:24:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-affera-sphere-9-for-cardiac-ablation-massdevice 2024-10-24T21:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-therapy-reduced-attacks-in-hereditary-angioedema-medpage-today 2024-10-24T21:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-editing-therapy-reduced-attacks-in-hereditary-angioedema-medpage-today 2024-10-24T21:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/onward-raises-54m-to-continue-neuromodulation-trials-clinical-trials-arena 2024-10-24T21:05:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onward-raises-54m-to-continue-neuromodulation-trials-clinical-trials-arena 2024-10-24T21:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-fda-approval-of-afferatm-mapping-and-ablation-system-and-sphere-9tm-catheter 2024-10-24T20:48:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-fda-approval-of-afferatm-mapping-and-ablation-system-and-sphere-9tm-catheter 2024-10-24T20:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/robotic-system-flags-potential-arrhythmia-therapies-inside-precision-medicine 2024-10-24T20:46:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/robotic-system-flags-potential-arrhythmia-therapies-inside-precision-medicine 2024-10-24T20:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/cervical-dystonia-pipeline-assessment-2024-comprehensive-openpr-com 2024-10-24T20:44:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervical-dystonia-pipeline-assessment-2024-comprehensive-openpr-com 2024-10-24T20:44:17+00:00 weekly 0.7 https://trial.medpath.com/news/recon-novo-nordisk-asks-fda-to-block-semaglutide-compounding-lilly-to-launch-obesity-raps 2024-10-24T20:42:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-novo-nordisk-asks-fda-to-block-semaglutide-compounding-lilly-to-launch-obesity-raps 2024-10-24T20:42:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-paradigm-in-electrophysiology-medtronic-receives-fda-approval-of-afferatm-mapping 2024-10-24T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-paradigm-in-electrophysiology-medtronic-receives-fda-approval-of-afferatm-mapping 2024-10-24T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-fda-approval-of-afferatm-mapping-and-ablation-system-and-sphere-9tm-catheter 2024-10-24T20:34:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-fda-approval-of-afferatm-mapping-and-ablation-system-and-sphere-9tm-catheter 2024-10-24T20:34:21+00:00 weekly 0.7 https://trial.medpath.com/news/local-patients-contribute-to-fda-approval-of-early-breast-cancer-drug-ksnv 2024-10-24T20:31:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/local-patients-contribute-to-fda-approval-of-early-breast-cancer-drug-ksnv 2024-10-24T20:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/dr-anne-marie-morse-on-the-significance-of-the-fda-s-approval-of-lumryz-for-pediatric-patients 2024-10-24T20:20:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-anne-marie-morse-on-the-significance-of-the-fda-s-approval-of-lumryz-for-pediatric-patients 2024-10-24T20:20:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-abbvie-therapy-for-adults-with-advanced-parkinson-s-disease-pharmtech 2024-10-24T20:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-abbvie-therapy-for-adults-with-advanced-parkinson-s-disease-pharmtech 2024-10-24T20:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/dr-patel-on-findings-from-the-trust-ii-trial-in-ros1-nsclc-onclive 2024-10-24T19:52:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-patel-on-findings-from-the-trust-ii-trial-in-ros1-nsclc-onclive 2024-10-24T19:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-tlx101-cdx-for-glioma-imaging-onclive 2024-10-24T19:52:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-tlx101-cdx-for-glioma-imaging-onclive 2024-10-24T19:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/first-patients-dosed-in-phase-1-clinical-study-of-immunitybio-s-car-nk-cell-therapy-for-the 2024-10-24T19:52:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patients-dosed-in-phase-1-clinical-study-of-immunitybio-s-car-nk-cell-therapy-for-the 2024-10-24T19:52:17+00:00 weekly 0.7 https://trial.medpath.com/news/toronto-firefighter-back-on-the-job-after-new-drug-slows-incurable-brain-cancer 2024-10-24T19:51:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toronto-firefighter-back-on-the-job-after-new-drug-slows-incurable-brain-cancer 2024-10-24T19:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-nda-for-lenz-therapeutics-lnz100-for-the-treatment-of-presbyopia 2024-10-24T19:50:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-nda-for-lenz-therapeutics-lnz100-for-the-treatment-of-presbyopia 2024-10-24T19:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharma-phase-3-trusttsc-trial-of-oral-ganaxolone-fails-stock-plunges 2024-10-24T19:40:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharma-phase-3-trusttsc-trial-of-oral-ganaxolone-fails-stock-plunges 2024-10-24T19:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-regimens-earn-european-approvals-in-gynecologic-cancers 2024-10-24T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-regimens-earn-european-approvals-in-gynecologic-cancers 2024-10-24T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/chemotherapy-combinations-and-the-phase-3-duo-e-trial-cancer-network 2024-10-24T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemotherapy-combinations-and-the-phase-3-duo-e-trial-cancer-network 2024-10-24T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-therapy-and-immunotherapy-improve-outcomes-in-rare-thyroid-cancer 2024-10-24T19:32:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-therapy-and-immunotherapy-improve-outcomes-in-rare-thyroid-cancer 2024-10-24T19:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/connecting-ayas-to-quality-cancer-care-nci 2024-10-24T19:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/connecting-ayas-to-quality-cancer-care-nci 2024-10-24T19:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-publication-in-cell-reports-demonstrating-xprotm-promotes 2024-10-24T19:20:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-announces-publication-in-cell-reports-demonstrating-xprotm-promotes 2024-10-24T19:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/new-analysis-links-novo-s-semaglutide-to-reduced-risk-of-alzheimer-s-disease-medwatch 2024-10-24T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-analysis-links-novo-s-semaglutide-to-reduced-risk-of-alzheimer-s-disease-medwatch 2024-10-24T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-first-in-class-drug-approved-for-advanced-stomach-cancer-webmd 2024-10-24T19:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-first-in-class-drug-approved-for-advanced-stomach-cancer-webmd 2024-10-24T19:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/approval-of-bevacizumab-biosimilar-could-eliminate-access-to-low-cost-amd-therapy 2024-10-24T19:01:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/approval-of-bevacizumab-biosimilar-could-eliminate-access-to-low-cost-amd-therapy 2024-10-24T19:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-utilizes-a-counterintuitive-approach-to-improve-metabolic-stability-of-an-hiv-protease-inhibitor 2024-10-24T18:54:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-utilizes-a-counterintuitive-approach-to-improve-metabolic-stability-of-an-hiv-protease-inhibitor 2024-10-24T18:54:26+00:00 weekly 0.7 https://trial.medpath.com/news/unravel-biosciences-and-pecet-announce-collaboration-to-conduct-clinical-trials-of-rvl 2024-10-24T18:51:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unravel-biosciences-and-pecet-announce-collaboration-to-conduct-clinical-trials-of-rvl 2024-10-24T18:51:46+00:00 weekly 0.7 https://trial.medpath.com/news/unravel-biosciences-and-pecet-announce-collaboration-to-conduct-clinical-trials-of-rvl 2024-10-24T18:38:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unravel-biosciences-and-pecet-announce-collaboration-to-conduct-clinical-trials-of-rvl 2024-10-24T18:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/mrd-a-game-changer-in-multiple-myeloma-american-journal-of-managed-care 2024-10-24T18:37:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrd-a-game-changer-in-multiple-myeloma-american-journal-of-managed-care 2024-10-24T18:37:02+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-biospace 2024-10-24T18:19:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-biospace 2024-10-24T18:19:17+00:00 weekly 0.7 https://trial.medpath.com/news/birchbiomed-clinical-program-reaches-final-stage-to-minimise-burn-scars 2024-10-24T18:14:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/birchbiomed-clinical-program-reaches-final-stage-to-minimise-burn-scars 2024-10-24T18:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/2024-regulatory-approvals-across-nsclc-propel-the-therapeutic-landscape-forward 2024-10-24T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-regulatory-approvals-across-nsclc-propel-the-therapeutic-landscape-forward 2024-10-24T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/combining-targeted-therapy-and-immunotherapy-improves-overall-survival-in-patients-with 2024-10-24T17:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combining-targeted-therapy-and-immunotherapy-improves-overall-survival-in-patients-with 2024-10-24T17:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/step-up-your-practice-start-treating-fip-today-dvm360 2024-10-24T17:33:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/step-up-your-practice-start-treating-fip-today-dvm360 2024-10-24T17:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-guidance-on-use-of-part-11-electronic-systems-records-and-signatures-in 2024-10-24T17:31:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-use-of-part-11-electronic-systems-records-and-signatures-in 2024-10-24T17:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/lack-of-support-for-dementia-carers-highlighted-as-clinical-trial-launched 2024-10-24T17:19:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lack-of-support-for-dementia-carers-highlighted-as-clinical-trial-launched 2024-10-24T17:19:56+00:00 weekly 0.7 https://trial.medpath.com/news/recent-fda-guidance-signals-future-growth-for-decentralized-clinical-trials 2024-10-24T17:12:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-fda-guidance-signals-future-growth-for-decentralized-clinical-trials 2024-10-24T17:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/anaphylm-sublingual-film-achieves-rapid-resolution-of-allergen-related-symptoms 2024-10-24T17:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anaphylm-sublingual-film-achieves-rapid-resolution-of-allergen-related-symptoms 2024-10-24T17:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-trials-raise-ethical-concerns-over-risk-disclosure-becker-s-hospital-review 2024-10-24T16:38:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-trials-raise-ethical-concerns-over-risk-disclosure-becker-s-hospital-review 2024-10-24T16:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/women-beginning-chemotherapy-for-breast-cancer-self-report-improved-cognitive 2024-10-24T16:37:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/women-beginning-chemotherapy-for-breast-cancer-self-report-improved-cognitive 2024-10-24T16:37:48+00:00 weekly 0.7 https://trial.medpath.com/news/drugs-like-ozempic-and-wegovy-are-linked-to-a-lower-risk-of-alzheimer-s-disease-new-study-says 2024-10-24T16:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drugs-like-ozempic-and-wegovy-are-linked-to-a-lower-risk-of-alzheimer-s-disease-new-study-says 2024-10-24T16:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2024 2024-10-24T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2024 2024-10-24T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2024 2024-10-24T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2024 2024-10-24T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/popular-diabetes-and-weight-loss-drug-may-reduce-risk-of-alzheimer-s-disease 2024-10-24T16:12:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/popular-diabetes-and-weight-loss-drug-may-reduce-risk-of-alzheimer-s-disease 2024-10-24T16:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-earns-eu-approval-in-2-new-indications-for-endometrial-and-cervical-cancer 2024-10-24T16:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-earns-eu-approval-in-2-new-indications-for-endometrial-and-cervical-cancer 2024-10-24T16:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-tlx101-cdx-pet-imaging-agent-in-glioma 2024-10-24T16:03:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-tlx101-cdx-pet-imaging-agent-in-glioma 2024-10-24T16:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-alzheimer-s-drug-could-save-lives-by-inducing-a-state-of-suspended-animation 2024-10-24T16:01:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-alzheimer-s-drug-could-save-lives-by-inducing-a-state-of-suspended-animation 2024-10-24T16:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/septerna-raises-288m-in-upsized-ipo-to-advance-novel-gpcr-targeting-drug-pipeline 2024-10-24T15:58:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/septerna-raises-288m-in-upsized-ipo-to-advance-novel-gpcr-targeting-drug-pipeline 2024-10-24T15:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-rise-up-study-of-mitapivat-for-scd-completes-enrollment 2024-10-24T15:32:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-rise-up-study-of-mitapivat-for-scd-completes-enrollment 2024-10-24T15:32:56+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-stock-plunges-after-phase-2-results-from-ntla-2002-study 2024-10-24T15:32:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-stock-plunges-after-phase-2-results-from-ntla-2002-study 2024-10-24T15:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-sets-trial-dosage-for-al001-lithium-therapy-alzheimer-s-news-today 2024-10-24T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-sets-trial-dosage-for-al001-lithium-therapy-alzheimer-s-news-today 2024-10-24T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-irinotecan-trifluridine-tipiracil-tas-102-plus-bevacizumab-as-a-later-line 2024-10-24T15:19:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-of-irinotecan-trifluridine-tipiracil-tas-102-plus-bevacizumab-as-a-later-line 2024-10-24T15:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-next-gen-pulsed-field-ablation-catheter-for-paroxysmal-atrial-fibrillation 2024-10-24T15:17:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-next-gen-pulsed-field-ablation-catheter-for-paroxysmal-atrial-fibrillation 2024-10-24T15:17:14+00:00 weekly 0.7 https://trial.medpath.com/news/okyo-pharma-doses-first-subject-in-ok-101-phase-ii-trial-for-ncp 2024-10-24T15:09:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/okyo-pharma-doses-first-subject-in-ok-101-phase-ii-trial-for-ncp 2024-10-24T15:09:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-24T15:03:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-24T15:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-topical-treatments-expand-options-for-dermatological-conditions-expert-highlights-ruxolitinib-and-roflumilast-advances 2024-10-24T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-topical-treatments-expand-options-for-dermatological-conditions-expert-highlights-ruxolitinib-and-roflumilast-advances 2024-10-24T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-presents-positive-results-from-the-phase-2-study-of-ntla-2002-an-investigational-in 2024-10-24T14:56:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-presents-positive-results-from-the-phase-2-study-of-ntla-2002-an-investigational-in 2024-10-24T14:56:31+00:00 weekly 0.7 https://trial.medpath.com/news/myelomatch-program-opens-enrollment-for-acute-myeloid-leukemia-and-mds-news-medical 2024-10-24T14:55:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myelomatch-program-opens-enrollment-for-acute-myeloid-leukemia-and-mds-news-medical 2024-10-24T14:55:32+00:00 weekly 0.7 https://trial.medpath.com/news/reading-the-signs-of-dementia-nature 2024-10-24T14:50:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reading-the-signs-of-dementia-nature 2024-10-24T14:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/euro-roundup-britain-proposes-postmarket-surveillance-law-in-first-major-update-to 2024-10-24T14:40:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/euro-roundup-britain-proposes-postmarket-surveillance-law-in-first-major-update-to 2024-10-24T14:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-disease-semaglutide-use-linked-to-lower-risk-medicalnewstoday 2024-10-24T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-disease-semaglutide-use-linked-to-lower-risk-medicalnewstoday 2024-10-24T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/nih-clinical-trial-will-test-precision-medicine-treatments-for-myeloid-cancers 2024-10-24T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-clinical-trial-will-test-precision-medicine-treatments-for-myeloid-cancers 2024-10-24T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/could-pdurs-be-the-game-changer-to-unlock-digital-therapeutics-td-securities 2024-10-24T14:29:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-pdurs-be-the-game-changer-to-unlock-digital-therapeutics-td-securities 2024-10-24T14:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-ozempic-may-reduce-risk-of-alzheimer-s-disease-study-cnbc 2024-10-24T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-s-ozempic-may-reduce-risk-of-alzheimer-s-disease-study-cnbc 2024-10-24T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-precision-medicine-trial-to-test-new-treatments-for-myeloid-cancers 2024-10-24T14:25:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-launches-precision-medicine-trial-to-test-new-treatments-for-myeloid-cancers 2024-10-24T14:25:35+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-kisunla-does-not-demonstrate-good-value-for-uk-s-nhs 2024-10-24T14:23:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-kisunla-does-not-demonstrate-good-value-for-uk-s-nhs 2024-10-24T14:23:22+00:00 weekly 0.7 https://trial.medpath.com/news/the-evolving-role-of-adjuvant-immunotherapy-in-resected-renal-cell-carcinoma 2024-10-24T14:22:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-evolving-role-of-adjuvant-immunotherapy-in-resected-renal-cell-carcinoma 2024-10-24T14:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/alto-neuroscience-s-depression-drug-trial-fails-at-phase-2-biopharma-reporter-com 2024-10-24T14:15:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alto-neuroscience-s-depression-drug-trial-fails-at-phase-2-biopharma-reporter-com 2024-10-24T14:15:28+00:00 weekly 0.7 https://trial.medpath.com/news/are-norovirus-vaccines-on-the-horizon-medpage-today 2024-10-24T14:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-norovirus-vaccines-on-the-horizon-medpage-today 2024-10-24T14:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/upcoming-discussion-on-recent-advances-in-head-and-neck-cancer-clinical-trials 2024-10-24T14:08:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upcoming-discussion-on-recent-advances-in-head-and-neck-cancer-clinical-trials 2024-10-24T14:08:02+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-lease-on-life-procedure-relieves-patients-tremors-in-both-hands-newsroom 2024-10-24T14:07:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-lease-on-life-procedure-relieves-patients-tremors-in-both-hands-newsroom 2024-10-24T14:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-drug-approved-in-uk-but-government-won-t-pay-for-it-euronews 2024-10-24T14:06:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-drug-approved-in-uk-but-government-won-t-pay-for-it-euronews 2024-10-24T14:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/ec-approves-darzalex-sc-with-vrd-for-newly-diagnosed-multiple-myeloma-patients 2024-10-24T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ec-approves-darzalex-sc-with-vrd-for-newly-diagnosed-multiple-myeloma-patients 2024-10-24T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/news/october-24-2024-apa-sm-trial-joins-the-nih-pragmatic-trials-collaboratory 2024-10-24T13:50:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-24-2024-apa-sm-trial-joins-the-nih-pragmatic-trials-collaboratory 2024-10-24T13:50:36+00:00 weekly 0.7 https://trial.medpath.com/news/icddr-b-s-breakthrough-research-leads-to-who-s-approval-of-single-dose-cecolin-vaccine-for 2024-10-24T13:46:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icddr-b-s-breakthrough-research-leads-to-who-s-approval-of-single-dose-cecolin-vaccine-for 2024-10-24T13:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/health-and-wellness-sector-sees-new-opportunities-in-weight-loss-drug-market 2024-10-24T13:45:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-and-wellness-sector-sees-new-opportunities-in-weight-loss-drug-market 2024-10-24T13:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-announces-sponsored-research-agreement-with-the-university-of-michigan-stock-titan 2024-10-24T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genprex-announces-sponsored-research-agreement-with-the-university-of-michigan-stock-titan 2024-10-24T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/aulos-bioscience-presents-phase-2-dose-selection-data-for-novel-il-2-therapeutic 2024-10-24T13:25:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aulos-bioscience-presents-phase-2-dose-selection-data-for-novel-il-2-therapeutic 2024-10-24T13:25:58+00:00 weekly 0.7 https://trial.medpath.com/news/health-check-approval-clock-ticks-as-fda-accepts-telix-s-brain-diagnostic-marketing-application 2024-10-24T13:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-check-approval-clock-ticks-as-fda-accepts-telix-s-brain-diagnostic-marketing-application 2024-10-24T13:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/new-hope-for-rapid-acting-depression-treatment-national-institute-of-mental-health 2024-10-24T13:07:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-hope-for-rapid-acting-depression-treatment-national-institute-of-mental-health 2024-10-24T13:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted 2024-10-24T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted 2024-10-24T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for 2024-10-24T13:05:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for 2024-10-24T13:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-stock-titan 2024-10-24T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-stock-titan 2024-10-24T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/iasis-molecular-takes-next-steps-to-develop-two-products-spokane-journal-of-business 2024-10-24T13:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iasis-molecular-takes-next-steps-to-develop-two-products-spokane-journal-of-business 2024-10-24T13:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/lytix-biopharma-highlights-positive-data-on-ltx-315-in-collaboration-with-verrica 2024-10-24T13:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lytix-biopharma-highlights-positive-data-on-ltx-315-in-collaboration-with-verrica 2024-10-24T13:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-reports-promising-phase-2-results-for-hae-treatment-investing-com 2024-10-24T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-reports-promising-phase-2-results-for-hae-treatment-investing-com 2024-10-24T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-morningstar 2024-10-24T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-morningstar 2024-10-24T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for 2024-10-24T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for 2024-10-24T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-analysis-shows-primec-significantly-improves-key-mirnas-in-als-patients 2024-10-24T12:41:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-analysis-shows-primec-significantly-improves-key-mirnas-in-als-patients 2024-10-24T12:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-announces-topline-results-from-phase-3-trusttsc-trial-of-oral 2024-10-24T12:20:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharmaceuticals-announces-topline-results-from-phase-3-trusttsc-trial-of-oral 2024-10-24T12:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/accent-therapeutics-announces-fda-clearance-of-ind-application-for-atx-559-a-first-in 2024-10-24T12:18:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accent-therapeutics-announces-fda-clearance-of-ind-application-for-atx-559-a-first-in 2024-10-24T12:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/lytix-biopharma-highlights-positive-data-on-ltx-315-in-collaboration-with-verrica-finansavisen 2024-10-24T12:16:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lytix-biopharma-highlights-positive-data-on-ltx-315-in-collaboration-with-verrica-finansavisen 2024-10-24T12:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/angiodynamics-launches-long-term-study-of-nanoknife-for-prostate-cancer 2024-10-24T12:15:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angiodynamics-launches-long-term-study-of-nanoknife-for-prostate-cancer 2024-10-24T12:15:58+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-late-breaking-positive-phase-3-data-globenewswire 2024-10-24T12:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-late-breaking-positive-phase-3-data-globenewswire 2024-10-24T12:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-prescriptions-for-type-1-diabetes-spike-despite-lack-of-fda-approval-study 2024-10-24T12:12:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-prescriptions-for-type-1-diabetes-spike-despite-lack-of-fda-approval-study 2024-10-24T12:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-24T12:09:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-24T12:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-global-phase-3-lugano-clinical 2024-10-24T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-global-phase-3-lugano-clinical 2024-10-24T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-24T12:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-24T12:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise 2024-10-24T12:07:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise 2024-10-24T12:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise 2024-10-24T12:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise 2024-10-24T12:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/medera-announces-completion-of-cohort-a-and-initiation-of-dosing-in-cohort-b-of-music 2024-10-24T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medera-announces-completion-of-cohort-a-and-initiation-of-dosing-in-cohort-b-of-music 2024-10-24T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-showcases-neuropsychiatry-innovations-at-psych-congress 2024-10-24T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-showcases-neuropsychiatry-innovations-at-psych-congress 2024-10-24T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-naked-biospace 2024-10-24T11:58:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-naked-biospace 2024-10-24T11:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2024 2024-10-24T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2024 2024-10-24T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/pcl-faces-allegations-of-clinical-trial-manipulation-for-covid-19-test-kit 2024-10-24T11:43:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pcl-faces-allegations-of-clinical-trial-manipulation-for-covid-19-test-kit 2024-10-24T11:43:35+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-and-ecog-acrin-partner-to-interrogate-landmark-tailorx-breast-cancer-trial 2024-10-24T11:34:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-and-ecog-acrin-partner-to-interrogate-landmark-tailorx-breast-cancer-trial 2024-10-24T11:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib 2024-10-24T11:20:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib 2024-10-24T11:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-s-prevail-dcb-pivotal-trial-receives-fda-ide-approval-medical-device-network 2024-10-24T11:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-s-prevail-dcb-pivotal-trial-receives-fda-ide-approval-medical-device-network 2024-10-24T11:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/calluna-completes-cal101-phase-i-clinical-study-for-fibrotic-conditions 2024-10-24T11:16:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calluna-completes-cal101-phase-i-clinical-study-for-fibrotic-conditions 2024-10-24T11:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage 2024-10-24T11:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage 2024-10-24T11:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-linked-to-lower-alzheimer-s-risk-in-people-with-type-2-diabetes-nbc-news 2024-10-24T11:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-linked-to-lower-alzheimer-s-risk-in-people-with-type-2-diabetes-nbc-news 2024-10-24T11:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-might-help-lower-alzheimer-s-risk-in-people-with-diabetes 2024-10-24T11:10:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-might-help-lower-alzheimer-s-risk-in-people-with-diabetes 2024-10-24T11:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-precision-medicine-trial-for-myeloid-cancers-clinical-trials-arena 2024-10-24T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-launches-precision-medicine-trial-for-myeloid-cancers-clinical-trials-arena 2024-10-24T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-pr-newswire 2024-10-24T11:07:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-pr-newswire 2024-10-24T11:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-announces-clinical-trial-milestone-in-phase-2b-microdosing-trials-targeting 2024-10-24T11:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindbio-announces-clinical-trial-milestone-in-phase-2b-microdosing-trials-targeting 2024-10-24T11:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib 2024-10-24T11:03:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib 2024-10-24T11:03:52+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-naked 2024-10-24T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-naked 2024-10-24T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/i-participated-in-the-first-fda-approved-stem-cell-trial-for-ms-it-changed-my-life-popsugar 2024-10-24T10:51:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-participated-in-the-first-fda-approved-stem-cell-trial-for-ms-it-changed-my-life-popsugar 2024-10-24T10:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/myelomatch-precision-medicine-trials-in-myelo-eurekalert 2024-10-24T10:48:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myelomatch-precision-medicine-trials-in-myelo-eurekalert 2024-10-24T10:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/medigene-ag-reports-financial-results-and-business-update-for-q3-2024-biospace 2024-10-24T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medigene-ag-reports-financial-results-and-business-update-for-q3-2024-biospace 2024-10-24T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-announce-1st-patient-dosed-in-phase-i-ii-of-pfl-002-vert-002-a-targeted 2024-10-24T10:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-announce-1st-patient-dosed-in-phase-i-ii-of-pfl-002-vert-002-a-targeted 2024-10-24T10:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical 2024-10-24T10:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical 2024-10-24T10:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/gold-sirna-supraclusters-enhance-the-anti-tumor-immune-response-of-stereotactic-ablative 2024-10-24T10:19:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gold-sirna-supraclusters-enhance-the-anti-tumor-immune-response-of-stereotactic-ablative 2024-10-24T10:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/implant-might-prevent-opioid-overdose 2024-10-24T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implant-might-prevent-opioid-overdose 2024-10-24T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/bicycle-switches-on-to-radiopharma-in-new-cancer-breakthrough-business-weekly 2024-10-24T08:32:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bicycle-switches-on-to-radiopharma-in-new-cancer-breakthrough-business-weekly 2024-10-24T08:32:08+00:00 weekly 0.7 https://trial.medpath.com/news/be-bio-raises-82m-to-advance-haemophilia-b-gene-therapy-to-phase-i-ii-trial 2024-10-24T07:59:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/be-bio-raises-82m-to-advance-haemophilia-b-gene-therapy-to-phase-i-ii-trial 2024-10-24T07:59:20+00:00 weekly 0.7 https://trial.medpath.com/news/expert-highlights-diagnostic-challenges-and-trial-access-barriers-in-myeloproliferative-neoplasms 2024-10-24T07:39:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-highlights-diagnostic-challenges-and-trial-access-barriers-in-myeloproliferative-neoplasms 2024-10-24T07:39:43+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-launches-obesity-drug-in-denmark-hits-shelves-next-week-medwatch 2024-10-24T07:35:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-launches-obesity-drug-in-denmark-hits-shelves-next-week-medwatch 2024-10-24T07:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-announce-1st-patient-dosed-in-phase-i-ii-of-pfl-002-vert-002-a-targeted 2024-10-24T07:27:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-announce-1st-patient-dosed-in-phase-i-ii-of-pfl-002-vert-002-a-targeted 2024-10-24T07:27:55+00:00 weekly 0.7 https://trial.medpath.com/news/supply-chain-evolution-critical-for-pharmaceutical-industry-s-shift-to-advanced-therapies 2024-10-24T07:26:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supply-chain-evolution-critical-for-pharmaceutical-industry-s-shift-to-advanced-therapies 2024-10-24T07:26:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-24T06:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-24T06:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/receives-u-s-fda-fast-track-designation-for-the-novel-anti-respiratory-syncytial-virus 2024-10-24T06:12:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/receives-u-s-fda-fast-track-designation-for-the-novel-anti-respiratory-syncytial-virus 2024-10-24T06:12:24+00:00 weekly 0.7 https://trial.medpath.com/news/j-ints-bio-presents-interim-findings-from-phase-1-2-clinical-trial-of-4th-generation-egfr 2024-10-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-ints-bio-presents-interim-findings-from-phase-1-2-clinical-trial-of-4th-generation-egfr 2024-10-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/tens-of-thousands-of-uk-dementia-patients-to-be-enrolled-in-clinical-trials-the-guardian 2024-10-24T05:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tens-of-thousands-of-uk-dementia-patients-to-be-enrolled-in-clinical-trials-the-guardian 2024-10-24T05:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes 2024-10-24T05:10:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes 2024-10-24T05:10:33+00:00 weekly 0.7 https://trial.medpath.com/news/evolving-complexity-in-ovarian-cancer-treatment-demands-better-decision-support-systems 2024-10-24T05:04:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolving-complexity-in-ovarian-cancer-treatment-demands-better-decision-support-systems 2024-10-24T05:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara-r-brain-cancer-imaging-agent 2024-10-24T03:10:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara-r-brain-cancer-imaging-agent 2024-10-24T03:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/federal-officials-should-investigate-conduct-of-alzheimer-s-disease-trials-public-citizen 2024-10-24T03:08:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/federal-officials-should-investigate-conduct-of-alzheimer-s-disease-trials-public-citizen 2024-10-24T03:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/supervised-machine-learning-emerges-as-preferred-ai-solution-for-clinical-trials-over-large-language-models 2024-10-24T02:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supervised-machine-learning-emerges-as-preferred-ai-solution-for-clinical-trials-over-large-language-models 2024-10-24T02:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/hybrid-software-approach-emerges-as-new-paradigm-in-drug-development 2024-10-24T01:47:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hybrid-software-approach-emerges-as-new-paradigm-in-drug-development 2024-10-24T01:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/expert-recommendations-for-germany-s-integration-of-psychedelic-assisted-therapy 2024-10-24T01:33:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-recommendations-for-germany-s-integration-of-psychedelic-assisted-therapy 2024-10-24T01:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/teva-s-denosumab-biosimilar-candidate-is-accepted-for-review-by-fda-and-ema 2024-10-24T01:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-s-denosumab-biosimilar-candidate-is-accepted-for-review-by-fda-and-ema 2024-10-24T01:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/on-the-nyt-article-what-drugmakers-did-not-tell-volunteers-in-alzheimer-s-trials 2024-10-24T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/on-the-nyt-article-what-drugmakers-did-not-tell-volunteers-in-alzheimer-s-trials 2024-10-24T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/everest-medicines-eyes-mrna-tumor-vaccines-as-drug-valuations-rebound-bamboo-works 2024-10-24T01:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/everest-medicines-eyes-mrna-tumor-vaccines-as-drug-valuations-rebound-bamboo-works 2024-10-24T01:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/intensive-chemotherapy-versus-standard-chemotherapy-among-patients-with-high-risk-the-bmj 2024-10-24T01:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intensive-chemotherapy-versus-standard-chemotherapy-among-patients-with-high-risk-the-bmj 2024-10-24T01:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/hope-medicine-inc-announces-positive-results-from-a-global-phase-2-study-of-a-first-in 2024-10-24T00:55:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-medicine-inc-announces-positive-results-from-a-global-phase-2-study-of-a-first-in 2024-10-24T00:55:20+00:00 weekly 0.7 https://trial.medpath.com/news/common-drug-shows-promise-in-extending-lifespan-usc-dornsife 2024-10-24T00:01:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/common-drug-shows-promise-in-extending-lifespan-usc-dornsife 2024-10-24T00:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-9-becomes-latest-radiopharma-to-secure-funds-with-175m-series-c 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-9-becomes-latest-radiopharma-to-secure-funds-with-175m-series-c 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aktis-oncology-s-first-in-class-nectin-4-radiopharmaceutical-aky-1189-shows-promising-tumor-uptake-across-multiple-cancer-types 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aktis-oncology-s-first-in-class-nectin-4-radiopharmaceutical-aky-1189-shows-promising-tumor-uptake-across-multiple-cancer-types 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/australian-court-invalidates-bayer-s-rivaroxaban-follow-on-patents-in-landmark-obviousness-ruling 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australian-court-invalidates-bayer-s-rivaroxaban-follow-on-patents-in-landmark-obviousness-ruling 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upadacitinib-in-adolescents-with-moderate-to-severe-atopic-dermatitis-jama-network 2024-10-23T23:49:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upadacitinib-in-adolescents-with-moderate-to-severe-atopic-dermatitis-jama-network 2024-10-23T23:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/woodcock-rct-standards-not-fit-for-rare-disease-treatment-approval 2024-10-23T22:29:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/woodcock-rct-standards-not-fit-for-rare-disease-treatment-approval 2024-10-23T22:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-and-grants-priority-review-globenewswire 2024-10-23T22:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-and-grants-priority-review-globenewswire 2024-10-23T22:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/dr-ducreux-on-the-potential-use-of-liver-transplantation-plus-chemo-for-crc-liver-metastases 2024-10-23T20:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-ducreux-on-the-potential-use-of-liver-transplantation-plus-chemo-for-crc-liver-metastases 2024-10-23T20:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-the-unilateral-authorization-of-sputnik-v-is-like-a-russian-roulette 2024-10-23T20:01:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-the-unilateral-authorization-of-sputnik-v-is-like-a-russian-roulette 2024-10-23T20:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/are-you-a-healthy-african-american-between-the-ages-of-18-and-60-the-reporter-uab 2024-10-23T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-you-a-healthy-african-american-between-the-ages-of-18-and-60-the-reporter-uab 2024-10-23T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-announces-device-trial-participation-snapshots-akin-gump 2024-10-23T19:33:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-announces-device-trial-participation-snapshots-akin-gump 2024-10-23T19:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/luna-diabetes-launches-trial-for-world-s-smallest-insulin-patch-pump 2024-10-23T18:25:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/luna-diabetes-launches-trial-for-world-s-smallest-insulin-patch-pump 2024-10-23T18:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fast-acting-novel-depression-tx-lumryz-label-expanded-glp-1s-for-addiction 2024-10-23T18:22:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fast-acting-novel-depression-tx-lumryz-label-expanded-glp-1s-for-addiction 2024-10-23T18:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/utility-of-a-systolic-blood-pressure-polygenic-risk-score-with-chlorthalidone-response 2024-10-23T18:03:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/utility-of-a-systolic-blood-pressure-polygenic-risk-score-with-chlorthalidone-response 2024-10-23T18:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-in-talks-with-sahpra-to-register-twice-yearly-anti-hiv-jab-juta-medicalbrief 2024-10-23T18:00:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-in-talks-with-sahpra-to-register-twice-yearly-anti-hiv-jab-juta-medicalbrief 2024-10-23T18:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/can-takeda-help-treat-narcolepsy-the-medicine-maker 2024-10-23T18:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-takeda-help-treat-narcolepsy-the-medicine-maker 2024-10-23T18:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/sangamo-to-seek-accelerated-approval-for-fabry-gene-therapy 2024-10-23T17:55:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sangamo-to-seek-accelerated-approval-for-fabry-gene-therapy 2024-10-23T17:55:33+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-heart-rate-control-with-ivabradine-on-hemodynamic-in-patients-with-sepsis-trials 2024-10-23T17:31:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-heart-rate-control-with-ivabradine-on-hemodynamic-in-patients-with-sepsis-trials 2024-10-23T17:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/redhill-duke-collaborate-on-phosgene-inhalation-treatment-contract-pharma 2024-10-23T17:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/redhill-duke-collaborate-on-phosgene-inhalation-treatment-contract-pharma 2024-10-23T17:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-10-23T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-10-23T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/cadonilimab-plus-chemo-an-option-for-cervical-cancer 2024-10-23T16:33:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cadonilimab-plus-chemo-an-option-for-cervical-cancer 2024-10-23T16:33:44+00:00 weekly 0.7 https://trial.medpath.com/news/hibercell-receives-fda-fast-track-designation-for-hc-7366-for-the-treatment-of-relapsed 2024-10-23T16:16:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hibercell-receives-fda-fast-track-designation-for-hc-7366-for-the-treatment-of-relapsed 2024-10-23T16:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/llnl-unveils-breakthrough-fentanyl-overdose-treatment-mirage-news 2024-10-23T15:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/llnl-unveils-breakthrough-fentanyl-overdose-treatment-mirage-news 2024-10-23T15:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/x-therma-announces-world-s-first-subzero-transatlantic-organ-transports 2024-10-23T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/x-therma-announces-world-s-first-subzero-transatlantic-organ-transports 2024-10-23T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-granted-extension-to-meet-nasdaq-listing-rules-investing-com-uk 2024-10-23T15:54:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lixte-biotechnology-granted-extension-to-meet-nasdaq-listing-rules-investing-com-uk 2024-10-23T15:54:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ide-for-medtronic-prevail-drug-coated-balloon 2024-10-23T15:42:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ide-for-medtronic-prevail-drug-coated-balloon 2024-10-23T15:42:43+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-therapy-to-prevent-or-delay-type-1-diabetes-now-available-at-unc-children-s-hospital 2024-10-23T15:26:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-therapy-to-prevent-or-delay-type-1-diabetes-now-available-at-unc-children-s-hospital 2024-10-23T15:26:06+00:00 weekly 0.7 https://trial.medpath.com/news/i-spy2-2-dato-dxd-plus-durvalumab-yields-high-pathologic-response-rate-in-breast 2024-10-23T15:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-spy2-2-dato-dxd-plus-durvalumab-yields-high-pathologic-response-rate-in-breast 2024-10-23T15:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-announces-first-patient-dosed-in-phase-2-clinical-study-of-rec-3964-a-potential 2024-10-23T15:14:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-announces-first-patient-dosed-in-phase-2-clinical-study-of-rec-3964-a-potential 2024-10-23T15:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-with-in-vivo-gene-therapy-for-car-t-inside-precision-medicine 2024-10-23T15:13:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-with-in-vivo-gene-therapy-for-car-t-inside-precision-medicine 2024-10-23T15:13:52+00:00 weekly 0.7 https://trial.medpath.com/news/modivcare-and-michigan-center-for-rural-health-partner-to-extend-care-access-by-quantisnow 2024-10-23T15:13:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modivcare-and-michigan-center-for-rural-health-partner-to-extend-care-access-by-quantisnow 2024-10-23T15:13:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-crl-for-ketamine-to-treat-pain-mental-health-and-more-hcplive 2024-10-23T15:05:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-crl-for-ketamine-to-treat-pain-mental-health-and-more-hcplive 2024-10-23T15:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity-healio 2024-10-23T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity-healio 2024-10-23T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-usefulness-of-digital-twin-guided-virtual-amiodarone-test-in-patients-with-atrial-nature 2024-10-23T14:49:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-usefulness-of-digital-twin-guided-virtual-amiodarone-test-in-patients-with-atrial-nature 2024-10-23T14:49:12+00:00 weekly 0.7 https://trial.medpath.com/news/disappointing-phase-2b-results-for-alto-100-for-mdd-precision-medicine 2024-10-23T14:46:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disappointing-phase-2b-results-for-alto-100-for-mdd-precision-medicine 2024-10-23T14:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/atorvastatin-and-telmisartan-do-not-reduce-nasopharyngeal-carriage-of-sars-cov-2-in-mild 2024-10-23T14:28:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atorvastatin-and-telmisartan-do-not-reduce-nasopharyngeal-carriage-of-sars-cov-2-in-mild 2024-10-23T14:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-transplant-noninferior-from-donors-with-versus-without-hiv-in-hiv-positive-recipients 2024-10-23T14:24:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-transplant-noninferior-from-donors-with-versus-without-hiv-in-hiv-positive-recipients 2024-10-23T14:24:43+00:00 weekly 0.7 https://trial.medpath.com/news/prescription-digital-therapeutic-for-insomnia-improves-sleep-and-mental-health-neurology-advisor 2024-10-23T14:24:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prescription-digital-therapeutic-for-insomnia-improves-sleep-and-mental-health-neurology-advisor 2024-10-23T14:24:35+00:00 weekly 0.7 https://trial.medpath.com/news/young-patient-s-recovery-from-debilitating-injury-inspires-return-to-miami-as-summer 2024-10-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/young-patient-s-recovery-from-debilitating-injury-inspires-return-to-miami-as-summer 2024-10-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-media-sees-up-to-62-of-alzheimer-s-study-randomizations-from-diverse-populations 2024-10-23T13:55:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-media-sees-up-to-62-of-alzheimer-s-study-randomizations-from-diverse-populations 2024-10-23T13:55:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-analysis-of-phase-3-data-demonstrating-renal-protective-benefits-of-sotagliflozin-to-be 2024-10-23T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-analysis-of-phase-3-data-demonstrating-renal-protective-benefits-of-sotagliflozin-to-be 2024-10-23T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/wobble-genomics-unveils-breakthrough-early-detection-tech-for-breast-cancer-mercia 2024-10-23T13:21:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wobble-genomics-unveils-breakthrough-early-detection-tech-for-breast-cancer-mercia 2024-10-23T13:21:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-slow-start-for-self-amplifying-mrna-vaccines-pharmaceutical-technology 2024-10-23T13:05:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-slow-start-for-self-amplifying-mrna-vaccines-pharmaceutical-technology 2024-10-23T13:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-1a-1b-study-of-fostroxacitabine-bralpamide-fostrox-monothera-jhc-dove-medical-press 2024-10-23T12:45:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-1a-1b-study-of-fostroxacitabine-bralpamide-fostrox-monothera-jhc-dove-medical-press 2024-10-23T12:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/join-biovie-s-exclusive-live-investor-webinar-and-q-a-session-on-november-7th-2024 2024-10-23T12:33:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/join-biovie-s-exclusive-live-investor-webinar-and-q-a-session-on-november-7th-2024 2024-10-23T12:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/calluna-pharma-completes-successful-phase-1-trial-of-new-fibrotic-disease-drug 2024-10-23T12:32:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calluna-pharma-completes-successful-phase-1-trial-of-new-fibrotic-disease-drug 2024-10-23T12:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-phase-ii-study-on-the-safety-of-intravitreal-nt-501-encapsulated-cell-therapy 2024-10-23T12:21:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-phase-ii-study-on-the-safety-of-intravitreal-nt-501-encapsulated-cell-therapy 2024-10-23T12:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/agios-completes-enrollment-of-phase-3-rise-up-study-of-mitapivat-in-sickle-cell-disease 2024-10-23T11:44:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-completes-enrollment-of-phase-3-rise-up-study-of-mitapivat-in-sickle-cell-disease 2024-10-23T11:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-sciences-covid-19-treatment-to-receive-reimbursement-pharma-article-kbr 2024-10-23T11:38:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-sciences-covid-19-treatment-to-receive-reimbursement-pharma-article-kbr 2024-10-23T11:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-updated-positive-safety-and-tolerability-results-from-the 2024-10-23T11:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-announces-updated-positive-safety-and-tolerability-results-from-the 2024-10-23T11:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/elan-class-action-news-elanco-animal-health-incorporated-globenewswire 2024-10-23T11:17:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elan-class-action-news-elanco-animal-health-incorporated-globenewswire 2024-10-23T11:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/oric-114-demonstrates-potential-in-preclinical-cancer-study 2024-10-23T11:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oric-114-demonstrates-potential-in-preclinical-cancer-study 2024-10-23T11:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/nma-reveals-vabysmo-s-superior-cst-improvement-over-eylea-hd 2024-10-23T10:45:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nma-reveals-vabysmo-s-superior-cst-improvement-over-eylea-hd 2024-10-23T10:45:17+00:00 weekly 0.7 https://trial.medpath.com/news/ps3m-for-world-first-trial-to-revolutionise-brain-cancer-treatment 2024-10-23T10:35:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ps3m-for-world-first-trial-to-revolutionise-brain-cancer-treatment 2024-10-23T10:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-alzheimer-s-drug-gets-uk-nod-but-won-t-be-nhs-funded-pharmaphorum 2024-10-23T10:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-alzheimer-s-drug-gets-uk-nod-but-won-t-be-nhs-funded-pharmaphorum 2024-10-23T10:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/covid-in-pregnancy-won-t-lead-to-neurodevelopmental-issues-in-kids 2024-10-23T10:02:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-in-pregnancy-won-t-lead-to-neurodevelopmental-issues-in-kids 2024-10-23T10:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/aerobic-exercise-may-ease-brain-fog-of-breast-cancer-chemo 2024-10-23T10:01:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aerobic-exercise-may-ease-brain-fog-of-breast-cancer-chemo 2024-10-23T10:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/mri-might-spare-rectal-cancer-patients-surgery-and-colostomy 2024-10-23T10:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mri-might-spare-rectal-cancer-patients-surgery-and-colostomy 2024-10-23T10:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/fully-automated-ai-based-system-developed-for-ivf-embryo-quality-assessment 2024-10-23T09:46:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fully-automated-ai-based-system-developed-for-ivf-embryo-quality-assessment 2024-10-23T09:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/aligos-therapeutics-announces-u-s-fda-clearance-of-ind-application-for-alg-000184 2024-10-23T09:20:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aligos-therapeutics-announces-u-s-fda-clearance-of-ind-application-for-alg-000184 2024-10-23T09:20:22+00:00 weekly 0.7 https://trial.medpath.com/news/positive-chmp-opinion-for-siiltibcy-tuberculosis-skin-test-webdisclosure 2024-10-23T08:21:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-chmp-opinion-for-siiltibcy-tuberculosis-skin-test-webdisclosure 2024-10-23T08:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/jiangsu-recbio-launches-phase-iii-trial-for-shingles-vaccine-markets-insider 2024-10-23T08:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jiangsu-recbio-launches-phase-iii-trial-for-shingles-vaccine-markets-insider 2024-10-23T08:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/methadone-outperforms-other-opioid-treatments-in-keeping-patients-in-care 2024-10-23T08:06:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/methadone-outperforms-other-opioid-treatments-in-keeping-patients-in-care 2024-10-23T08:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/panavance-details-ind-prep-ahead-of-fda-submission-for-ovarian-cancer-trial 2024-10-23T07:12:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/panavance-details-ind-prep-ahead-of-fda-submission-for-ovarian-cancer-trial 2024-10-23T07:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-biomedical-inc-announces-king-s-college-hospital-to-run-steriwave-pilot-webdisclosure 2024-10-23T06:11:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ondine-biomedical-inc-announces-king-s-college-hospital-to-run-steriwave-pilot-webdisclosure 2024-10-23T06:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-expects-eu-decision-on-bioarctic-s-lecanemab-in-q2-marketscreener 2024-10-23T05:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-expects-eu-decision-on-bioarctic-s-lecanemab-in-q2-marketscreener 2024-10-23T05:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-strong-globenewswire 2024-10-23T05:03:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-strong-globenewswire 2024-10-23T05:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-revolution-how-patient-insights-are-transforming-modern-drug-development 2024-10-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-centric-revolution-how-patient-insights-are-transforming-modern-drug-development 2024-10-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-mandatory-clinical-trial-training-in-hematology-oncology-fellowship-programs 2024-10-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-mandatory-clinical-trial-training-in-hematology-oncology-fellowship-programs 2024-10-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/grx-biosims-panelists-discuss-regulatory-shifts-in-biosimilar-interchangeability 2024-10-23T02:09:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grx-biosims-panelists-discuss-regulatory-shifts-in-biosimilar-interchangeability 2024-10-23T02:09:43+00:00 weekly 0.7 https://trial.medpath.com/news/it-was-just-so-quick-new-drug-to-help-patients-like-mark-before-it-s-too-late-daily-liberal 2024-10-23T02:07:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/it-was-just-so-quick-new-drug-to-help-patients-like-mark-before-it-s-too-late-daily-liberal 2024-10-23T02:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/long-acting-hiv-therapies-show-promise-amid-policy-challenges-idweek-2024-highlights 2024-10-23T01:55:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-acting-hiv-therapies-show-promise-amid-policy-challenges-idweek-2024-highlights 2024-10-23T01:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/the-one-mutation-that-could-change-cancer-therapy-forever-synbiobeta 2024-10-23T01:24:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-one-mutation-that-could-change-cancer-therapy-forever-synbiobeta 2024-10-23T01:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-wonder-drug-will-be-blocked-by-nhs-from-today-due-to-cost-daily-mail 2024-10-23T01:12:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-wonder-drug-will-be-blocked-by-nhs-from-today-due-to-cost-daily-mail 2024-10-23T01:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/mind-diet-and-cognitive-decline-gene-therapy-for-parkinson-s-curbing-ms-fatigue 2024-10-23T01:07:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mind-diet-and-cognitive-decline-gene-therapy-for-parkinson-s-curbing-ms-fatigue 2024-10-23T01:07:19+00:00 weekly 0.7 https://trial.medpath.com/news/ocuphire-pharma-acquires-opus-genetics-modern-retina 2024-10-22T22:54:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocuphire-pharma-acquires-opus-genetics-modern-retina 2024-10-22T22:54:38+00:00 weekly 0.7 https://trial.medpath.com/news/algorae-pharmaceuticals-launches-ai-platform-and-advances-drug-trials-tipranks-com 2024-10-22T22:51:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/algorae-pharmaceuticals-launches-ai-platform-and-advances-drug-trials-tipranks-com 2024-10-22T22:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/siemens-healthineers-wins-fda-nod-for-heart-attack-predicting-test-massdevice 2024-10-22T22:45:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siemens-healthineers-wins-fda-nod-for-heart-attack-predicting-test-massdevice 2024-10-22T22:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-gentuity-imaging-system-for-coronary-interventions-massdevice 2024-10-22T22:43:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-gentuity-imaging-system-for-coronary-interventions-massdevice 2024-10-22T22:43:30+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-glue-two-proteins-together-driving-cancer-cells-to-self-destruct-news-center 2024-10-22T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-glue-two-proteins-together-driving-cancer-cells-to-self-destruct-news-center 2024-10-22T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/carmen-lc03-tusamitamab-ravtansine-vs-docetaxel-in-previously-treated-advanced 2024-10-22T21:37:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carmen-lc03-tusamitamab-ravtansine-vs-docetaxel-in-previously-treated-advanced 2024-10-22T21:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/genelux-corporation-announces-first-patient-dosed-in-phase-2-trial-evaluating-systemic 2024-10-22T21:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genelux-corporation-announces-first-patient-dosed-in-phase-2-trial-evaluating-systemic 2024-10-22T21:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/on-off-switch-for-car-t-cell-therapy-shows-early-promise-inside-precision-medicine 2024-10-22T20:57:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/on-off-switch-for-car-t-cell-therapy-shows-early-promise-inside-precision-medicine 2024-10-22T20:57:23+00:00 weekly 0.7 https://trial.medpath.com/news/dbv-announces-positive-regulatory-updates-for-the-viaskin-r-globenewswire 2024-10-22T20:56:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dbv-announces-positive-regulatory-updates-for-the-viaskin-r-globenewswire 2024-10-22T20:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/cothera-bioscience-announces-fda-fast-track-designation-for-clinical-program-pc-002 2024-10-22T20:55:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cothera-bioscience-announces-fda-fast-track-designation-for-clinical-program-pc-002 2024-10-22T20:55:23+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-pfizer-s-rsv-vaccine-abrysvo-r-for-adults-aged-18-to-59-at-increased 2024-10-22T20:54:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-pfizer-s-rsv-vaccine-abrysvo-r-for-adults-aged-18-to-59-at-increased 2024-10-22T20:54:38+00:00 weekly 0.7 https://trial.medpath.com/news/recon-fda-rejects-camurus-rare-hormone-disorder-drug-amgen-to-launch-eylea-raps 2024-10-22T20:23:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-fda-rejects-camurus-rare-hormone-disorder-drug-amgen-to-launch-eylea-raps 2024-10-22T20:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-for-biktarvy-issued-to-gilead-sciences-inc-quantisnow 2024-10-22T20:19:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-for-biktarvy-issued-to-gilead-sciences-inc-quantisnow 2024-10-22T20:19:38+00:00 weekly 0.7 https://trial.medpath.com/news/gyre-therapeutics-announces-last-patient-completed-pivotal-phase-3-trial-evaluating 2024-10-22T20:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gyre-therapeutics-announces-last-patient-completed-pivotal-phase-3-trial-evaluating 2024-10-22T20:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemotherapy-becomes-leading-initial-treatment-for-advanced-epithelial 2024-10-22T19:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-chemotherapy-becomes-leading-initial-treatment-for-advanced-epithelial 2024-10-22T19:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/oncternal-therapeutics-announces-updated-safety-and-efficacy-data-for-phase-1-2-study-of 2024-10-22T19:04:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncternal-therapeutics-announces-updated-safety-and-efficacy-data-for-phase-1-2-study-of 2024-10-22T19:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-to-receive-breakthrough-sickle-cell-gene-therapy-leaves-hospital 2024-10-22T18:55:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-to-receive-breakthrough-sickle-cell-gene-therapy-leaves-hospital 2024-10-22T18:55:12+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-to-present-latest-research-across-key-liver-disease-indication-at-the-american 2024-10-22T18:41:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-to-present-latest-research-across-key-liver-disease-indication-at-the-american 2024-10-22T18:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/nido-biosciences-announces-orphan-drug-designation-for-lead-clinical-candidate-to-treat 2024-10-22T18:37:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nido-biosciences-announces-orphan-drug-designation-for-lead-clinical-candidate-to-treat 2024-10-22T18:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to 2024-10-22T18:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to 2024-10-22T18:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/me-therapeutics-holdings-inc-provides-research-and-development-update-and-corporate-update 2024-10-22T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/me-therapeutics-holdings-inc-provides-research-and-development-update-and-corporate-update 2024-10-22T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/a-common-genetic-variant-may-guide-precision-therapy-for-sickle-cell-disease 2024-10-22T17:45:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-common-genetic-variant-may-guide-precision-therapy-for-sickle-cell-disease 2024-10-22T17:45:09+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-clinical-trial-pipeline-gains-momentum-180-companies-lead-the-charge 2024-10-22T17:14:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-clinical-trial-pipeline-gains-momentum-180-companies-lead-the-charge 2024-10-22T17:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-efficacy-and-safety-of-ocrelizumab-biosimilar-xacrel-compared-to-the-originator 2024-10-22T16:58:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-efficacy-and-safety-of-ocrelizumab-biosimilar-xacrel-compared-to-the-originator 2024-10-22T16:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/outcomes-with-adjuvant-ici-treatment-in-resected-stage-iii-iv-melanoma-the-asco-post 2024-10-22T16:53:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outcomes-with-adjuvant-ici-treatment-in-resected-stage-iii-iv-melanoma-the-asco-post 2024-10-22T16:53:29+00:00 weekly 0.7 https://trial.medpath.com/news/cosmetic-outcomes-with-two-schedules-of-partial-breast-irradiation-in-early-breast-cancer 2024-10-22T16:48:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cosmetic-outcomes-with-two-schedules-of-partial-breast-irradiation-in-early-breast-cancer 2024-10-22T16:48:31+00:00 weekly 0.7 https://trial.medpath.com/news/peytant-wins-fda-de-novo-nod-for-covered-stent-system-massdevice 2024-10-22T16:28:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/peytant-wins-fda-de-novo-nod-for-covered-stent-system-massdevice 2024-10-22T16:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-to-highlight-buntanetap-s-alzheimer-s-research-progress-with-presentations-at-ctad-2024 2024-10-22T16:28:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annovis-to-highlight-buntanetap-s-alzheimer-s-research-progress-with-presentations-at-ctad-2024 2024-10-22T16:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/study-pharmacokinetics-safety-comparable-between-ct-p13-autoinjector-and-pre-filled-syringe 2024-10-22T16:20:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-pharmacokinetics-safety-comparable-between-ct-p13-autoinjector-and-pre-filled-syringe 2024-10-22T16:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/celmatix-achieves-milestone-in-development-of-oral-fertility-drug-femtech-insider 2024-10-22T16:11:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celmatix-achieves-milestone-in-development-of-oral-fertility-drug-femtech-insider 2024-10-22T16:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/omega-3s-for-heart-health-exploring-potential-benefits-and-risks-nhlbi 2024-10-22T16:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omega-3s-for-heart-health-exploring-potential-benefits-and-risks-nhlbi 2024-10-22T16:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/vivos-therapeutics-secures-fda-clearance-for-pediatric-osa-device-secures-new-ama-cpt-codes 2024-10-22T16:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivos-therapeutics-secures-fda-clearance-for-pediatric-osa-device-secures-new-ama-cpt-codes 2024-10-22T16:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/zoledronic-acid-treatment-reduces-fracture-rate-in-pediatric-patients 2024-10-22T15:58:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zoledronic-acid-treatment-reduces-fracture-rate-in-pediatric-patients 2024-10-22T15:58:14+00:00 weekly 0.7 https://trial.medpath.com/news/topical-on101-is-superior-to-conventional-dressing-for-some-diabetic-foot-ulcers 2024-10-22T15:58:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topical-on101-is-superior-to-conventional-dressing-for-some-diabetic-foot-ulcers 2024-10-22T15:58:13+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-tops-other-antibodies-at-binding-soluble-ab-aggregates-alzforum 2024-10-22T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-tops-other-antibodies-at-binding-soluble-ab-aggregates-alzforum 2024-10-22T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/have-you-been-diagnosed-with-lupus-the-reporter-uab 2024-10-22T15:52:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/have-you-been-diagnosed-with-lupus-the-reporter-uab 2024-10-22T15:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/heal-initiative-jcoin-phase-ii-community-engaged-research-resource-center-josh-gottheimer 2024-10-22T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heal-initiative-jcoin-phase-ii-community-engaged-research-resource-center-josh-gottheimer 2024-10-22T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/roche-trims-another-alzheimer-s-prospect-ending-ucb-collabortion-biospace 2024-10-22T15:37:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-trims-another-alzheimer-s-prospect-ending-ucb-collabortion-biospace 2024-10-22T15:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/telo-genomics-corp-presents-new-performance-data-for-its-smoldering-myeloma-prognostic-test 2024-10-22T15:37:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telo-genomics-corp-presents-new-performance-data-for-its-smoldering-myeloma-prognostic-test 2024-10-22T15:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/hansoh-pharmaceutical-group-company-limited-announces-phase-iii-registrational-trial 2024-10-22T15:15:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hansoh-pharmaceutical-group-company-limited-announces-phase-iii-registrational-trial 2024-10-22T15:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/vcu-liver-specialist-partners-with-patient-group-to-study-rare-diseases-impact 2024-10-22T15:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vcu-liver-specialist-partners-with-patient-group-to-study-rare-diseases-impact 2024-10-22T15:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/complement-activation-and-lung-injury-in-japanese-patients-with-covid-19-nature 2024-10-22T15:01:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/complement-activation-and-lung-injury-in-japanese-patients-with-covid-19-nature 2024-10-22T15:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/prausnitz-elected-to-national-academy-of-medicine-georgia-tech-college-of-engineering 2024-10-22T14:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prausnitz-elected-to-national-academy-of-medicine-georgia-tech-college-of-engineering 2024-10-22T14:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-drug-for-motor-neurone-disease-shows-promise-in-new-study-durham-university 2024-10-22T14:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-drug-for-motor-neurone-disease-shows-promise-in-new-study-durham-university 2024-10-22T14:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/post-transplant-lymphoproliferative-disorder-drug-pipeline-globenewswire 2024-10-22T13:58:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-transplant-lymphoproliferative-disorder-drug-pipeline-globenewswire 2024-10-22T13:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/cogt-stock-hits-52-week-high-at-12-2-amid-market-optimism 2024-10-22T13:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cogt-stock-hits-52-week-high-at-12-2-amid-market-optimism 2024-10-22T13:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/artera-receives-california-lab-license-expanding-access-to-its-arteraai-prostate-test 2024-10-22T13:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artera-receives-california-lab-license-expanding-access-to-its-arteraai-prostate-test 2024-10-22T13:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/fiocruz-will-lead-the-first-clinical-trial-of-a-leprosy-vaccine-in-brazil 2024-10-22T13:16:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fiocruz-will-lead-the-first-clinical-trial-of-a-leprosy-vaccine-in-brazil 2024-10-22T13:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/sangamo-therapeutics-announces-alignment-with-fda-on-accelerated-approval-pathway 2024-10-22T13:02:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sangamo-therapeutics-announces-alignment-with-fda-on-accelerated-approval-pathway 2024-10-22T13:02:57+00:00 weekly 0.7 https://trial.medpath.com/news/the-effect-of-coaching-on-health-information-literacy-in-patients-with-chronic-kidney-disease 2024-10-22T12:48:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-effect-of-coaching-on-health-information-literacy-in-patients-with-chronic-kidney-disease 2024-10-22T12:48:56+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-neurological-treatment-polish-researchers-develop-promising-new-molecule 2024-10-22T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-neurological-treatment-polish-researchers-develop-promising-new-molecule 2024-10-22T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-presents-rationale-design-for-study-evaluating-pds01adc-tipranks 2024-10-22T12:19:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-presents-rationale-design-for-study-evaluating-pds01adc-tipranks 2024-10-22T12:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-announces-further-international-globenewswire 2024-10-22T12:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-announces-further-international-globenewswire 2024-10-22T12:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/autobahn-therapeutics-announces-fda-clearance-of-ind-application-for-abx-002-as-an 2024-10-22T12:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autobahn-therapeutics-announces-fda-clearance-of-ind-application-for-abx-002-as-an 2024-10-22T12:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-completion-of-screening-in-phase-2b-progress-study-of-lx9211-stock-titan 2024-10-22T12:01:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-announces-completion-of-screening-in-phase-2b-progress-study-of-lx9211-stock-titan 2024-10-22T12:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/awakn-announces-opening-of-four-additional-awkn-001-phase-3-trial-sites 2024-10-22T11:47:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/awakn-announces-opening-of-four-additional-awkn-001-phase-3-trial-sites 2024-10-22T11:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/gradient-denervation-technologies-appoints-stanton-rowe-to-board-of-directors-morningstar 2024-10-22T11:37:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gradient-denervation-technologies-appoints-stanton-rowe-to-board-of-directors-morningstar 2024-10-22T11:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/first-participants-enrolled-in-first-in-human-phase-i-clinical-trial-with-nociceptin-nop-receptor-agonist 2024-10-22T11:32:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-participants-enrolled-in-first-in-human-phase-i-clinical-trial-with-nociceptin-nop-receptor-agonist 2024-10-22T11:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-declines-to-approve-camurus-rare-hormone-disorder-drug-the-mighty-790-kfgo 2024-10-22T11:24:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-declines-to-approve-camurus-rare-hormone-disorder-drug-the-mighty-790-kfgo 2024-10-22T11:24:11+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi 2024-10-22T11:17:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi 2024-10-22T11:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/data-and-safety-monitoring-board-approves-initiation-of-phase-2-of-ocu410st-globenewswire 2024-10-22T11:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-and-safety-monitoring-board-approves-initiation-of-phase-2-of-ocu410st-globenewswire 2024-10-22T11:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/athira-pharma-to-present-results-from-phase-2-3-lift-ad-clinical-trial-of-fosgonimeton-at 2024-10-22T11:07:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/athira-pharma-to-present-results-from-phase-2-3-lift-ad-clinical-trial-of-fosgonimeton-at 2024-10-22T11:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-announces-bepranemab-phase-2a-study-results-accepted-for-late-breaking 2024-10-22T11:03:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-announces-bepranemab-phase-2a-study-results-accepted-for-late-breaking 2024-10-22T11:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-announces-positive-outcome-of-interim-analysis-of-phase-3-ensure-program-of 2024-10-22T10:54:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-announces-positive-outcome-of-interim-analysis-of-phase-3-ensure-program-of 2024-10-22T10:54:55+00:00 weekly 0.7 https://trial.medpath.com/news/otsuka-eyes-early-filing-of-igan-drug-after-phase-3-readout-pharmaphorum 2024-10-22T10:44:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/otsuka-eyes-early-filing-of-igan-drug-after-phase-3-readout-pharmaphorum 2024-10-22T10:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-inc-announces-positive-topline-results-from-phase-ib-ii-clinical 2024-10-22T10:13:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minghui-pharmaceutical-inc-announces-positive-topline-results-from-phase-ib-ii-clinical 2024-10-22T10:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/could-caffeine-in-pregnancy-help-prevent-cerebral-palsy-in-kids 2024-10-22T10:05:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-caffeine-in-pregnancy-help-prevent-cerebral-palsy-in-kids 2024-10-22T10:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/light-therapy-might-help-ease-dry-form-of-macular-degeneration 2024-10-22T10:01:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/light-therapy-might-help-ease-dry-form-of-macular-degeneration 2024-10-22T10:01:08+00:00 weekly 0.7 https://trial.medpath.com/news/help-therapeutics-secures-fda-approval-for-phase-i-study-of-hicm-188-in-heart-failure-treatment 2024-10-22T09:56:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/help-therapeutics-secures-fda-approval-for-phase-i-study-of-hicm-188-in-heart-failure-treatment 2024-10-22T09:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/our-viewpoint-new-aids-drug-the-witness 2024-10-22T09:27:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/our-viewpoint-new-aids-drug-the-witness 2024-10-22T09:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/ariceum-therapeutics-presents-promising-data-on-225ac-satoreotide-at-eanm-2024 2024-10-22T08:30:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ariceum-therapeutics-presents-promising-data-on-225ac-satoreotide-at-eanm-2024 2024-10-22T08:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/expert-outlines-strategies-to-improve-access-and-diversity-in-hr-her2-breast-cancer-clinical-trials 2024-10-22T08:25:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-outlines-strategies-to-improve-access-and-diversity-in-hr-her2-breast-cancer-clinical-trials 2024-10-22T08:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/assessing-the-effectiveness-and-safety-of-virtual-reality-in-treating-functional-dyspepsia 2024-10-22T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assessing-the-effectiveness-and-safety-of-virtual-reality-in-treating-functional-dyspepsia 2024-10-22T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/pyc-provides-an-interim-update-on-progress-in-rp11-repeat-dose-clinical-trials-biotech 2024-10-22T06:43:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pyc-provides-an-interim-update-on-progress-in-rp11-repeat-dose-clinical-trials-biotech 2024-10-22T06:43:15+00:00 weekly 0.7 https://trial.medpath.com/news/faron-s-capital-markets-day-2024-cision-news 2024-10-22T06:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/faron-s-capital-markets-day-2024-cision-news 2024-10-22T06:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/akiram-therapeutics-drug-candidate-akir001-cleared-to-start-phase-1-clinical-trial 2024-10-22T06:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akiram-therapeutics-drug-candidate-akir001-cleared-to-start-phase-1-clinical-trial 2024-10-22T06:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-sues-mangorx-over-alleged-tirzepatide-weight-loss-drug-copycats 2024-10-22T05:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-sues-mangorx-over-alleged-tirzepatide-weight-loss-drug-copycats 2024-10-22T05:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-disruption-patterns-reveal-regional-variations-and-rising-role-of-decentralized-studies 2024-10-22T05:15:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-disruption-patterns-reveal-regional-variations-and-rising-role-of-decentralized-studies 2024-10-22T05:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-pfizers-rsv-vaccine-abrysvo-for-adults-aged-18-to-59-at-increased-risk-for-disease 2024-10-22T05:10:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-pfizers-rsv-vaccine-abrysvo-for-adults-aged-18-to-59-at-increased-risk-for-disease 2024-10-22T05:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-experts-outline-strategies-to-combat-patient-retention-and-manufacturing-challenges 2024-10-22T04:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-experts-outline-strategies-to-combat-patient-retention-and-manufacturing-challenges 2024-10-22T04:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aekn-expanding-its-label-to-include-further-indications-approved-for-reference-product-stelara-ustekinumab 2024-10-22T04:10:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aekn-expanding-its-label-to-include-further-indications-approved-for-reference-product-stelara-ustekinumab 2024-10-22T04:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/reflexology-shows-promise-in-reducing-stress-and-pain-for-breast-cancer-patients-during-radiotherapy 2024-10-22T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reflexology-shows-promise-in-reducing-stress-and-pain-for-breast-cancer-patients-during-radiotherapy 2024-10-22T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uptake-of-health-economic-evaluations-alongside-clinical-trials-in-australia-an-observational-study 2024-10-22T01:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uptake-of-health-economic-evaluations-alongside-clinical-trials-in-australia-an-observational-study 2024-10-22T01:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/revolution-medicines-announces-first-patient-dosed-in-phase-3-study-evaluating-rmc 2024-10-22T01:55:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolution-medicines-announces-first-patient-dosed-in-phase-3-study-evaluating-rmc 2024-10-22T01:55:51+00:00 weekly 0.7 https://trial.medpath.com/news/europe-s-clinical-trial-leadership-declines-as-china-doubles-market-share-over-past-decade 2024-10-22T01:52:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-s-clinical-trial-leadership-declines-as-china-doubles-market-share-over-past-decade 2024-10-22T01:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/darling-ingredients-announces-publication-of-peer-reviewed-collagen-peptides-study-and-its-impact-on-post-meal-blood-glucose-spikes 2024-10-22T01:10:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darling-ingredients-announces-publication-of-peer-reviewed-collagen-peptides-study-and-its-impact-on-post-meal-blood-glucose-spikes 2024-10-22T01:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/france-imposes-strict-conditions-on-sanofi-s-eur16-billion-opella-healthcare-sale-to-cd-r 2024-10-22T00:40:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/france-imposes-strict-conditions-on-sanofi-s-eur16-billion-opella-healthcare-sale-to-cd-r 2024-10-22T00:40:07+00:00 weekly 0.7 https://trial.medpath.com/news/indaptus-therapeutics-announces-clinical-supply 2024-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indaptus-therapeutics-announces-clinical-supply 2024-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-recalls-7107-bottles-of-generic-duloxetine-over-carcinogenic-chemical-contamination 2024-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-recalls-7107-bottles-of-generic-duloxetine-over-carcinogenic-chemical-contamination 2024-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/research-finds-breakthrough-in-autoimmune-therapy-mirage-news 2024-10-21T23:39:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-finds-breakthrough-in-autoimmune-therapy-mirage-news 2024-10-21T23:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/recce-from-no-more-tears-to-no-more-superbug-fears-forbes-australia 2024-10-21T21:35:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-from-no-more-tears-to-no-more-superbug-fears-forbes-australia 2024-10-21T21:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-trials-provide-oncology-fellows-with-valuable-clinical-research-experience-onclive 2024-10-21T21:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-trials-provide-oncology-fellows-with-valuable-clinical-research-experience-onclive 2024-10-21T21:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-scores-2-key-fda-approvals-for-pfa-mapping-technology 2024-10-21T20:58:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-scores-2-key-fda-approvals-for-pfa-mapping-technology 2024-10-21T20:58:37+00:00 weekly 0.7 https://trial.medpath.com/news/recon-sanofi-in-talks-to-sell-its-consumer-business-opella-novo-s-rybelsus-cut-heart-risks-raps 2024-10-21T20:27:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-sanofi-in-talks-to-sell-its-consumer-business-opella-novo-s-rybelsus-cut-heart-risks-raps 2024-10-21T20:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/irhythm-technologies-receives-fda-510-k-clearance-for-design-updates-previously 2024-10-21T20:22:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irhythm-technologies-receives-fda-510-k-clearance-for-design-updates-previously 2024-10-21T20:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-announces-publication-of-positive-phase-2-results-of-solengepras-for-the-biospace 2024-10-21T18:21:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerevance-announces-publication-of-positive-phase-2-results-of-solengepras-for-the-biospace 2024-10-21T18:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/abionyx-pharma-received-positive-feedback-from-the-ema-for-cer-001-in-lcat-deficiency 2024-10-21T18:14:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abionyx-pharma-received-positive-feedback-from-the-ema-for-cer-001-in-lcat-deficiency 2024-10-21T18:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-receives-u-s-fda-approval-of-new-drug-application-for-pyridostigmine-bromide 2024-10-21T17:52:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-receives-u-s-fda-approval-of-new-drug-application-for-pyridostigmine-bromide 2024-10-21T17:52:27+00:00 weekly 0.7 https://trial.medpath.com/news/nonopioid-suzetrigine-demonstrates-positive-phase-3-results-for-acute-pain-asa-2024 2024-10-21T17:37:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nonopioid-suzetrigine-demonstrates-positive-phase-3-results-for-acute-pain-asa-2024 2024-10-21T17:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/rogaratinib-atezolizumab-in-cisplatin-ineligible-fgfr-mrna-overexpressing-urothelial-cancer 2024-10-21T16:42:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rogaratinib-atezolizumab-in-cisplatin-ineligible-fgfr-mrna-overexpressing-urothelial-cancer 2024-10-21T16:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/funda-meric-bernstam-m-d-elected-to-national-academy-of-medicine 2024-10-21T16:33:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/funda-meric-bernstam-m-d-elected-to-national-academy-of-medicine 2024-10-21T16:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-two-year-antibody-persistence-and-safety-of-a-single-dose-live-attenuated 2024-10-21T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-two-year-antibody-persistence-and-safety-of-a-single-dose-live-attenuated 2024-10-21T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/special-session-bill-will-allow-marshall-clinic-to-study-medication-assisted-treatment 2024-10-21T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/special-session-bill-will-allow-marshall-clinic-to-study-medication-assisted-treatment 2024-10-21T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/communities-that-heal-intervention-and-mortality-including-polysubstance-overdose-deaths 2024-10-21T15:55:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/communities-that-heal-intervention-and-mortality-including-polysubstance-overdose-deaths 2024-10-21T15:55:41+00:00 weekly 0.7 https://trial.medpath.com/news/endospan-hits-enrolment-milestone-in-aortic-arch-stent-trial-medical-device-network 2024-10-21T15:41:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endospan-hits-enrolment-milestone-in-aortic-arch-stent-trial-medical-device-network 2024-10-21T15:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-hd-treatments-to-market-the-role-of-regulatory-oversight-hdbuzz 2024-10-21T15:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bringing-hd-treatments-to-market-the-role-of-regulatory-oversight-hdbuzz 2024-10-21T15:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/three-vs-6-cycles-of-chemotherapy-for-high-risk-retinoblastoma-a-randomized-clinical-trial 2024-10-21T15:31:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-vs-6-cycles-of-chemotherapy-for-high-risk-retinoblastoma-a-randomized-clinical-trial 2024-10-21T15:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/expert-reaction-to-study-looking-at-a-home-based-transcranial-direct-current-stimulation 2024-10-21T15:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-reaction-to-study-looking-at-a-home-based-transcranial-direct-current-stimulation 2024-10-21T15:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-arcutis-zoryve-foam-for-seborrheic-dermatitis 2024-10-21T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-canada-approves-arcutis-zoryve-foam-for-seborrheic-dermatitis 2024-10-21T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/a-propensity-score-matching-study-nature 2024-10-21T14:44:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-propensity-score-matching-study-nature 2024-10-21T14:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/why-lenz-therapeutics-stock-hit-a-new-52-week-high-today-benzinga 2024-10-21T14:39:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-lenz-therapeutics-stock-hit-a-new-52-week-high-today-benzinga 2024-10-21T14:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/seaport-therapeutics-winds-up-usd-225mn-series-b-financing-round 2024-10-21T14:37:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seaport-therapeutics-winds-up-usd-225mn-series-b-financing-round 2024-10-21T14:37:28+00:00 weekly 0.7 https://trial.medpath.com/news/through-a-13m-nci-grant-a-team-of-massey-scientists-could-change-the-way-liver-cancer-is-treated 2024-10-21T14:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/through-a-13m-nci-grant-a-team-of-massey-scientists-could-change-the-way-liver-cancer-is-treated 2024-10-21T14:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/3-2-million-per-dose-elevidys-fails-to-meet-primary-endpoint-in-phase-3-trial 2024-10-21T14:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-2-million-per-dose-elevidys-fails-to-meet-primary-endpoint-in-phase-3-trial 2024-10-21T14:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/percutaneous-arterial-bypass-for-long-fem-pop-lesions-uses-expand-as-experience-mounts 2024-10-21T14:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/percutaneous-arterial-bypass-for-long-fem-pop-lesions-uses-expand-as-experience-mounts 2024-10-21T14:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/find-therapeutics-dosing-subjects-in-study-of-ftx-101-for-chronic-optic-neuropathy 2024-10-21T14:00:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/find-therapeutics-dosing-subjects-in-study-of-ftx-101-for-chronic-optic-neuropathy 2024-10-21T14:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/nvo-breakthrough-rybelsus-reduces-heart-attack-and-stroke-risk-in-study-gurufocus 2024-10-21T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvo-breakthrough-rybelsus-reduces-heart-attack-and-stroke-risk-in-study-gurufocus 2024-10-21T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/reduced-inflammation-in-axspa-does-not-always-translate-into-clinical-improvement 2024-10-21T13:29:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reduced-inflammation-in-axspa-does-not-always-translate-into-clinical-improvement 2024-10-21T13:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/ema-to-work-more-closely-with-the-european-commission-on-assessments-medwatch 2024-10-21T13:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-to-work-more-closely-with-the-european-commission-on-assessments-medwatch 2024-10-21T13:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-announces-fast-track-designation-for-intravenous-choline-chloride 2024-10-21T12:58:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-therapeutics-announces-fast-track-designation-for-intravenous-choline-chloride 2024-10-21T12:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/october-21-2024-best-icu-and-chat-4-heart-health-have-updated-study-snapshots 2024-10-21T12:50:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-21-2024-best-icu-and-chat-4-heart-health-have-updated-study-snapshots 2024-10-21T12:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/inovio-announces-new-data-at-scientific-conferences-for-lead-candidate-ino-3107-as-a 2024-10-21T12:39:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inovio-announces-new-data-at-scientific-conferences-for-lead-candidate-ino-3107-as-a 2024-10-21T12:39:50+00:00 weekly 0.7 https://trial.medpath.com/news/veru-to-present-at-obesityweek-meta-analysis-of-4-previous-randomized-clinical-trials 2024-10-21T12:37:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veru-to-present-at-obesityweek-meta-analysis-of-4-previous-randomized-clinical-trials 2024-10-21T12:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-announces-ketamir-2-outperforms-current-fda-approved-newswire 2024-10-21T12:25:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-announces-ketamir-2-outperforms-current-fda-approved-newswire 2024-10-21T12:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-to-host-participate-in-two-public-webinars-during-october-stock-titan 2024-10-21T12:12:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantern-pharma-to-host-participate-in-two-public-webinars-during-october-stock-titan 2024-10-21T12:12:29+00:00 weekly 0.7 https://trial.medpath.com/news/nevada-king-intercepts-9-1m-of-4-32-g-t-au-extending-mineralization-420 2024-10-21T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nevada-king-intercepts-9-1m-of-4-32-g-t-au-extending-mineralization-420 2024-10-21T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-to-present-at-the-thinkequity-conference-on-october-30th-globenewswire 2024-10-21T12:06:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/windtree-to-present-at-the-thinkequity-conference-on-october-30th-globenewswire 2024-10-21T12:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/biomed-industries-presents-phase-i-results-of-its-oral-quadruple-receptor-agonist-na-931 2024-10-21T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomed-industries-presents-phase-i-results-of-its-oral-quadruple-receptor-agonist-na-931 2024-10-21T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trials-of-pd-1-pd-l1-inhibitors-in-nmibc-urology-times 2024-10-21T12:05:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trials-of-pd-1-pd-l1-inhibitors-in-nmibc-urology-times 2024-10-21T12:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-globenewswire 2024-10-21T12:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-globenewswire 2024-10-21T12:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4-s-nsclc-therapy-yahoo 2024-10-21T11:41:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4-s-nsclc-therapy-yahoo 2024-10-21T11:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-reports-positive-phase-2-results-for-cdi-treatment-ibezapolstat-by-investing-com 2024-10-21T11:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-reports-positive-phase-2-results-for-cdi-treatment-ibezapolstat-by-investing-com 2024-10-21T11:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in 2024-10-21T11:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in 2024-10-21T11:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/fibrobiologics-charles-river-agree-on-therapies-manufacture-pharmaceutical-technology 2024-10-21T11:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fibrobiologics-charles-river-agree-on-therapies-manufacture-pharmaceutical-technology 2024-10-21T11:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/nuclidium-s-copper-based-radiotracer-shows-enhanced-imaging-performance-in-first-prostate-cancer-patient 2024-10-21T10:59:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuclidium-s-copper-based-radiotracer-shows-enhanced-imaging-performance-in-first-prostate-cancer-patient 2024-10-21T10:59:39+00:00 weekly 0.7 https://trial.medpath.com/news/news-engineered-polymers-show-promise-for-systemic-mrna-delivery-to-lungs 2024-10-21T10:58:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-engineered-polymers-show-promise-for-systemic-mrna-delivery-to-lungs 2024-10-21T10:58:17+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-biospace 2024-10-21T10:41:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-biospace 2024-10-21T10:41:02+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-frailty-scale-score-is-a-predictor-of-short-mid-and-long-term-mortality-in-critically-ill 2024-10-21T10:35:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-frailty-scale-score-is-a-predictor-of-short-mid-and-long-term-mortality-in-critically-ill 2024-10-21T10:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-receives-positive-chmp-opinions-for-tevimbra-r-as-a-first-line-treatment-via-ritzau 2024-10-21T10:27:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-receives-positive-chmp-opinions-for-tevimbra-r-as-a-first-line-treatment-via-ritzau 2024-10-21T10:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-might-spot-women-in-labor-at-risk-for-preeclampsia 2024-10-21T10:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-test-might-spot-women-in-labor-at-risk-for-preeclampsia 2024-10-21T10:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/tenaya-therapeutics-cleared-to-move-onto-higher-dose-cohort-in-trial-of-hypertrophic 2024-10-21T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenaya-therapeutics-cleared-to-move-onto-higher-dose-cohort-in-trial-of-hypertrophic 2024-10-21T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/after-shingles-damaged-her-vision-this-former-eye-surgeon-looked-for-a-way-to-keep-it-from 2024-10-21T08:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-shingles-damaged-her-vision-this-former-eye-surgeon-looked-for-a-way-to-keep-it-from 2024-10-21T08:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/senolytics-to-slow-progression-of-sepsis-stop-sepsis-in-elderly-patients-study-protocol-trials 2024-10-21T08:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senolytics-to-slow-progression-of-sepsis-stop-sepsis-in-elderly-patients-study-protocol-trials 2024-10-21T08:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/astex-pharmaceuticals-announce-key-data-presentations-at-the-36th-eortc-nci-aacr 2024-10-21T08:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astex-pharmaceuticals-announce-key-data-presentations-at-the-36th-eortc-nci-aacr 2024-10-21T08:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/new-podcast-kidney-compass-launches-to-navigate-complex-landscape-of-nephrology-clinical-trials 2024-10-21T08:00:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-podcast-kidney-compass-launches-to-navigate-complex-landscape-of-nephrology-clinical-trials 2024-10-21T08:00:52+00:00 weekly 0.7 https://trial.medpath.com/news/dr-john-conibear-on-the-evolution-of-durvalumab-in-nsclc-care 2024-10-21T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-john-conibear-on-the-evolution-of-durvalumab-in-nsclc-care 2024-10-21T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-ten-new-medicines-medwatch 2024-10-21T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-ten-new-medicines-medwatch 2024-10-21T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/lindis-biotech-receives-positive-chmp-opinion-for-korjuny-r-catumaxomab-in-eqs-news 2024-10-21T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lindis-biotech-receives-positive-chmp-opinion-for-korjuny-r-catumaxomab-in-eqs-news 2024-10-21T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-developments-epilepsy-trials-research-tree 2024-10-21T06:22:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-developments-epilepsy-trials-research-tree 2024-10-21T06:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-of 2024-10-21T06:01:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-of 2024-10-21T06:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-technologies-transform-quality-assurance-in-emerging-cell-and-gene-therapies 2024-10-21T05:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-technologies-transform-quality-assurance-in-emerging-cell-and-gene-therapies 2024-10-21T05:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectable-hepatocellular-carcinoma 2024-10-21T05:10:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectable-hepatocellular-carcinoma 2024-10-21T05:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia 2024-10-21T05:10:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia 2024-10-21T05:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/understanding-alternative-pathways-to-access-non-fda-approved-medications-a-comprehensive-review 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/understanding-alternative-pathways-to-access-non-fda-approved-medications-a-comprehensive-review 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/washington-university-s-clinical-trial-development-program-shows-success-in-training-future-investigators 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/washington-university-s-clinical-trial-development-program-shows-success-in-training-future-investigators 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-biotechnology-and-cyanvac-announce-presentation-on-intranasal-vaccine 2024-10-21T04:21:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-lake-biotechnology-and-cyanvac-announce-presentation-on-intranasal-vaccine 2024-10-21T04:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/hyperbaric-oxygen-therapy-in-the-treatment-of-late-onset-hemorrhagic-cystitis-after 2024-10-21T04:07:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hyperbaric-oxygen-therapy-in-the-treatment-of-late-onset-hemorrhagic-cystitis-after 2024-10-21T04:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-eyepoint-s-eyp-1901-proves-non-inferiority-to-aflibercept-in-davio-2 2024-10-21T02:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-eyepoint-s-eyp-1901-proves-non-inferiority-to-aflibercept-in-davio-2 2024-10-21T02:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-rezolute-s-rz-402-shows-promising-phase-iia-results-in-dme-patients 2024-10-21T01:37:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-rezolute-s-rz-402-shows-promising-phase-iia-results-in-dme-patients 2024-10-21T01:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/durga-borkar-md-phase-2-results-of-onl1204-for-rhegmatogenous-retinal-detachment 2024-10-21T01:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/durga-borkar-md-phase-2-results-of-onl1204-for-rhegmatogenous-retinal-detachment 2024-10-21T01:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-announces-first-in-human-phase-i-study-of-imp761-progresses-to-dose 2024-10-21T00:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-announces-first-in-human-phase-i-study-of-imp761-progresses-to-dose 2024-10-21T00:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/aprogen-a-company-specializing-in-antibody-drug-development-announced-on-the-21st-that 2024-10-21T00:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aprogen-a-company-specializing-in-antibody-drug-development-announced-on-the-21st-that 2024-10-21T00:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-restarts-in-accent-pancreatic-cancer-trial-biomelbourne-network 2024-10-21T00:38:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recruitment-restarts-in-accent-pancreatic-cancer-trial-biomelbourne-network 2024-10-21T00:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/everest-medicines-announces-taiwan-tfda-approval-of-nefecon-r-for-the-treatment-of 2024-10-21T00:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/everest-medicines-announces-taiwan-tfda-approval-of-nefecon-r-for-the-treatment-of 2024-10-21T00:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/glecirasib-pancreatic-cancer-indication-received-orphan 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glecirasib-pancreatic-cancer-indication-received-orphan 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accelerated-approval-and-confirmatory-trials-timing-is-everything 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accelerated-approval-and-confirmatory-trials-timing-is-everything 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-biopharmaceuticals-boosts-confidence-with-phase-3-plans-tipranks-com 2024-10-20T23:49:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-biopharmaceuticals-boosts-confidence-with-phase-3-plans-tipranks-com 2024-10-20T23:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/pursuecare-revives-fda-approved-digital-therapeutics-for-addiction-treatment 2024-10-20T23:18:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pursuecare-revives-fda-approved-digital-therapeutics-for-addiction-treatment 2024-10-20T23:18:56+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-clinical-trial-for-treating-spinal-cord-injury-griffith-news 2024-10-20T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-clinical-trial-for-treating-spinal-cord-injury-griffith-news 2024-10-20T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/news/pyc-therapeutics-gains-fda-approval-for-orphan-drug-tipranks-com 2024-10-20T22:54:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pyc-therapeutics-gains-fda-approval-for-orphan-drug-tipranks-com 2024-10-20T22:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/woman-finds-hope-in-new-ms-treatment-wvir 2024-10-20T22:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/woman-finds-hope-in-new-ms-treatment-wvir 2024-10-20T22:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/roger-a-goldberg-md-pooled-visual-function-data-of-nt-501-for-mactel-hcplive 2024-10-20T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roger-a-goldberg-md-pooled-visual-function-data-of-nt-501-for-mactel-hcplive 2024-10-20T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/understanding-the-nuances-of-the-rsv-maternal-vaccine-and-monoclonal-antibody-for-the 2024-10-20T21:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/understanding-the-nuances-of-the-rsv-maternal-vaccine-and-monoclonal-antibody-for-the 2024-10-20T21:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-developments-in-mrna-and-car-t-cell-therapies-reshape-cancer-treatment-landscape 2024-10-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-developments-in-mrna-and-car-t-cell-therapies-reshape-cancer-treatment-landscape 2024-10-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-and-survival-of-non-metastatic-small-cell-carcinoma-of-the-bladder-from-multiple 2024-10-20T20:47:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-and-survival-of-non-metastatic-small-cell-carcinoma-of-the-bladder-from-multiple 2024-10-20T20:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/low-intensity-shockwave-therapy-plasma-injections-efficacious-for-erectile-dysfunction 2024-10-20T20:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-intensity-shockwave-therapy-plasma-injections-efficacious-for-erectile-dysfunction 2024-10-20T20:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/aft-enters-late-stage-r-d-agreement-for-a-novel-injectable-nzx 2024-10-20T19:45:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aft-enters-late-stage-r-d-agreement-for-a-novel-injectable-nzx 2024-10-20T19:45:40+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-efgartigimod-ph20-efficacious-in-patients-with-cidp-previously-treated 2024-10-20T19:06:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-efgartigimod-ph20-efficacious-in-patients-with-cidp-previously-treated 2024-10-20T19:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-explore-how-a-community-practice-implemented-bispecific-antibody 2024-10-20T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-explore-how-a-community-practice-implemented-bispecific-antibody 2024-10-20T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-injectable-endothelial-cell-therapy-shows-promise-for-improving-vision-and 2024-10-20T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-injectable-endothelial-cell-therapy-shows-promise-for-improving-vision-and 2024-10-20T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/can-sharks-cure-cancer-uw-madison-research-shows-positive-advancements-wmtv 2024-10-20T17:29:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-sharks-cure-cancer-uw-madison-research-shows-positive-advancements-wmtv 2024-10-20T17:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/flt3-inhibitor-gilteritinib-may-also-be-effective-as-alk-inhibitor-in-aml 2024-10-20T16:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flt3-inhibitor-gilteritinib-may-also-be-effective-as-alk-inhibitor-in-aml 2024-10-20T16:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-two-year-clinical-feasibility-trial-outcomes-for-a-dual-optic-iol-system-for-the 2024-10-20T16:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-two-year-clinical-feasibility-trial-outcomes-for-a-dual-optic-iol-system-for-the 2024-10-20T16:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/oral-treatment-aims-to-reduce-ga-progression-by-slowing-vitamin-a-dimerization-healio 2024-10-20T15:35:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-treatment-aims-to-reduce-ga-progression-by-slowing-vitamin-a-dimerization-healio 2024-10-20T15:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/trs01-drops-display-favorable-clinical-profile-for-non-infectious-uveitis-hcplive 2024-10-20T15:17:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trs01-drops-display-favorable-clinical-profile-for-non-infectious-uveitis-hcplive 2024-10-20T15:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-myopic-lasik-performed-using-a-novel-excimer-laser-ophthalmology-times 2024-10-20T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-myopic-lasik-performed-using-a-novel-excimer-laser-ophthalmology-times 2024-10-20T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/hallmarks-of-a-genomically-distinct-subclass-of-head-and-neck-cancer-nature 2024-10-20T14:39:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hallmarks-of-a-genomically-distinct-subclass-of-head-and-neck-cancer-nature 2024-10-20T14:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-new-gene-therapy-shows-promise-for-treatment-of-retinitis-pigmentosa 2024-10-20T14:18:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-new-gene-therapy-shows-promise-for-treatment-of-retinitis-pigmentosa 2024-10-20T14:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/ctdna-clearance-confers-responses-to-radiation-in-gynecologic-malignancies 2024-10-20T14:09:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ctdna-clearance-confers-responses-to-radiation-in-gynecologic-malignancies 2024-10-20T14:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-clinical-trials-of-travoprost-ophthalmology-times-europe 2024-10-20T14:05:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-clinical-trials-of-travoprost-ophthalmology-times-europe 2024-10-20T14:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-jabs-for-unemployed-not-dystopian-says-wes-streeting-bbc 2024-10-20T13:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-jabs-for-unemployed-not-dystopian-says-wes-streeting-bbc 2024-10-20T13:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/cch-appears-safe-efficacious-in-peyronie-disease-with-ventral-curvature-urology-times 2024-10-20T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cch-appears-safe-efficacious-in-peyronie-disease-with-ventral-curvature-urology-times 2024-10-20T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/low-blood-s-methyl-5-thioadenosine-is-associated-with-postoperative-delayed-nature 2024-10-20T12:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-blood-s-methyl-5-thioadenosine-is-associated-with-postoperative-delayed-nature 2024-10-20T12:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/foresee-pharmaceuticals-announces-preliminary-results-from-a-phase-1-clinical-trial 2024-10-20T12:36:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-announces-preliminary-results-from-a-phase-1-clinical-trial 2024-10-20T12:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/national-fellows-forum-showcases-next-generation-of-lung-cancer-clinicians-onclive 2024-10-20T12:05:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-fellows-forum-showcases-next-generation-of-lung-cancer-clinicians-onclive 2024-10-20T12:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/philadelphia-hospitals-test-new-strategy-for-tranq-dope-withdrawal-ems1 2024-10-20T12:04:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philadelphia-hospitals-test-new-strategy-for-tranq-dope-withdrawal-ems1 2024-10-20T12:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/hospital-recruits-five-tiny-babies-for-feeding-study-bbc 2024-10-20T11:52:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hospital-recruits-five-tiny-babies-for-feeding-study-bbc 2024-10-20T11:52:40+00:00 weekly 0.7 https://trial.medpath.com/news/letter-collins-goes-above-and-beyond-for-alzheimer-s-patients-the-portland-press-herald 2024-10-20T11:08:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/letter-collins-goes-above-and-beyond-for-alzheimer-s-patients-the-portland-press-herald 2024-10-20T11:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/how-bad-is-this-news-for-novavax 2024-10-20T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-bad-is-this-news-for-novavax 2024-10-20T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-study-demonstrates-the-first-successful-clinical-application-of-antifibrotic-therapy-for-breast-cancer 2024-10-20T09:10:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-study-demonstrates-the-first-successful-clinical-application-of-antifibrotic-therapy-for-breast-cancer 2024-10-20T09:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-approaches-to-address-patient-fears-regarding-jak-inhibitor-safety 2024-10-20T09:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-identifies-approaches-to-address-patient-fears-regarding-jak-inhibitor-safety 2024-10-20T09:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/there-is-a-rare-disease-called-idiopathic-pulmonary-fibrosis-ipf-in-which-the-lungs-slowly-harden 2024-10-20T08:28:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/there-is-a-rare-disease-called-idiopathic-pulmonary-fibrosis-ipf-in-which-the-lungs-slowly-harden 2024-10-20T08:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/expert-takeaway-from-wclc-congress-highlights-innovative-acd-showing-promise-in-sclc 2024-10-20T07:02:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-takeaway-from-wclc-congress-highlights-innovative-acd-showing-promise-in-sclc 2024-10-20T07:02:06+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-boosts-heart-health-weight-loss-but-may-lead-to-gut-problems 2024-10-20T05:25:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-boosts-heart-health-weight-loss-but-may-lead-to-gut-problems 2024-10-20T05:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-clinical-efficacy-endpoints-from-the-phase-3-canopy-study-evaluating-pemivibart 2024-10-20T02:23:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-clinical-efficacy-endpoints-from-the-phase-3-canopy-study-evaluating-pemivibart 2024-10-20T02:23:31+00:00 weekly 0.7 https://trial.medpath.com/news/distinct-molecular-profiles-and-shared-drug-vulnerabilities-in-pancreatic-metastases-of-renal 2024-10-20T01:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/distinct-molecular-profiles-and-shared-drug-vulnerabilities-in-pancreatic-metastases-of-renal 2024-10-20T01:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/pulsed-shortwave-therapy-did-not-reduce-pain-scores-or-opioid-consumption-after-surgery 2024-10-19T23:37:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulsed-shortwave-therapy-did-not-reduce-pain-scores-or-opioid-consumption-after-surgery 2024-10-19T23:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-vorasidenib-for-idh-mutant-gliomas-survivornet 2024-10-19T23:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-approved-vorasidenib-for-idh-mutant-gliomas-survivornet 2024-10-19T23:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/kerala-joins-icmr-s-clinical-trial-for-indigenous-dengue-vaccine-the-south-first 2024-10-19T23:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kerala-joins-icmr-s-clinical-trial-for-indigenous-dengue-vaccine-the-south-first 2024-10-19T23:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/1-reason-to-buy-eli-lilly-stock-hand-over-fist-right-now-the-globe-and-mail 2024-10-19T22:37:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1-reason-to-buy-eli-lilly-stock-hand-over-fist-right-now-the-globe-and-mail 2024-10-19T22:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/tuhura-biosciences-announces-completion-of-merger-transaction-with-kintara-therapeutics 2024-10-19T21:29:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tuhura-biosciences-announces-completion-of-merger-transaction-with-kintara-therapeutics 2024-10-19T21:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-anti-tau-antibodies-under-clinical-trials-and-their-epitopes-on-tau-pathologies 2024-10-19T20:30:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparing-anti-tau-antibodies-under-clinical-trials-and-their-epitopes-on-tau-pathologies 2024-10-19T20:30:59+00:00 weekly 0.7 https://trial.medpath.com/news/professor-matt-dun-to-be-awarded-australian-society-for-medical-research-medal-hmri 2024-10-19T18:41:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/professor-matt-dun-to-be-awarded-australian-society-for-medical-research-medal-hmri 2024-10-19T18:41:59+00:00 weekly 0.7 https://trial.medpath.com/news/elevatum-study-s-reason-to-be-underrepresentation-in-clinical-trials-aao-2024 2024-10-19T18:22:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevatum-study-s-reason-to-be-underrepresentation-in-clinical-trials-aao-2024 2024-10-19T18:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-the-efficacy-of-support-groups-in-the-metaverse-for-ukrainian-refugees-trials 2024-10-19T17:34:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-the-efficacy-of-support-groups-in-the-metaverse-for-ukrainian-refugees-trials 2024-10-19T17:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-has-superior-response-rates-in-cml-oncology-nursing-news 2024-10-19T17:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asciminib-has-superior-response-rates-in-cml-oncology-nursing-news 2024-10-19T17:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-reveals-minimal-cognitive-gains-from-antipsychotic-drugs-medical-xpress 2024-10-19T16:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-reveals-minimal-cognitive-gains-from-antipsychotic-drugs-medical-xpress 2024-10-19T16:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/complete-consolidative-radiotherapy-may-have-survival-benefits-in-es-sclc 2024-10-19T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/complete-consolidative-radiotherapy-may-have-survival-benefits-in-es-sclc 2024-10-19T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-novel-approach-to-chronic-gvhd-with-axatilimab-dr-daniel-wolff 2024-10-19T15:44:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-novel-approach-to-chronic-gvhd-with-axatilimab-dr-daniel-wolff 2024-10-19T15:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/gvhd-cannot-be-wholly-prevented-so-effective-treatments-are-needed-says-dr-daniel-wolff 2024-10-19T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gvhd-cannot-be-wholly-prevented-so-effective-treatments-are-needed-says-dr-daniel-wolff 2024-10-19T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-nicotine-inhaler-for-smoking-cessation-moves-to-trial-phase-kfyr 2024-10-19T13:17:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-nicotine-inhaler-for-smoking-cessation-moves-to-trial-phase-kfyr 2024-10-19T13:17:29+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-presents-positive-results-from-the-ongoing-clinical-trial-of-its-btk 2024-10-19T12:28:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-presents-positive-results-from-the-ongoing-clinical-trial-of-its-btk 2024-10-19T12:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immune-checkpoint-inhibitor-therapy-improves-outcomes-in-early-breast-cancer 2024-10-19T11:59:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immune-checkpoint-inhibitor-therapy-improves-outcomes-in-early-breast-cancer 2024-10-19T11:59:41+00:00 weekly 0.7 https://trial.medpath.com/news/zakharia-evaluates-available-combination-options-for-non-clear-cell-rcc 2024-10-19T11:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zakharia-evaluates-available-combination-options-for-non-clear-cell-rcc 2024-10-19T11:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-treatment-for-regeneration-of-the-rotator-cuff-study-protocol-for-a-prospective-single 2024-10-19T11:50:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-treatment-for-regeneration-of-the-rotator-cuff-study-protocol-for-a-prospective-single 2024-10-19T11:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-the-british-biotech-disrupting-cancer-treatment-share-talk 2024-10-19T11:24:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-the-british-biotech-disrupting-cancer-treatment-share-talk 2024-10-19T11:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-study-reports-similar-efficacy-between-sb17-stelara-in-psoriasis 2024-10-19T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-study-reports-similar-efficacy-between-sb17-stelara-in-psoriasis 2024-10-19T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatments-enhance-care-for-diverse-range-of-patients-with-psoriasis 2024-10-19T10:46:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatments-enhance-care-for-diverse-range-of-patients-with-psoriasis 2024-10-19T10:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/common-cholesterol-drug-slows-mental-decline-from-alzheimer-s-disease 2024-10-19T10:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/common-cholesterol-drug-slows-mental-decline-from-alzheimer-s-disease 2024-10-19T10:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-reveals-elevated-triglyceride-levels-in-major-depressive-disorder-patients 2024-10-19T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-reveals-elevated-triglyceride-levels-in-major-depressive-disorder-patients 2024-10-19T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/three-year-results-for-eylea-hd-r-aflibercept-injection-8-globenewswire 2024-10-19T09:06:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-year-results-for-eylea-hd-r-aflibercept-injection-8-globenewswire 2024-10-19T09:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-io-io-data-contest-the-role-of-frontline-tkis-in-advanced-rcc-onclive 2024-10-19T08:09:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-io-io-data-contest-the-role-of-frontline-tkis-in-advanced-rcc-onclive 2024-10-19T08:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/integrated-cardio-renal-metabolic-care-models-face-implementation-challenges-despite-promise 2024-10-19T07:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/integrated-cardio-renal-metabolic-care-models-face-implementation-challenges-despite-promise 2024-10-19T07:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/no-link-found-between-prenatal-cannabis-use-and-early-childhood-disorders 2024-10-19T07:15:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-link-found-between-prenatal-cannabis-use-and-early-childhood-disorders 2024-10-19T07:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/wma-updates-declaration-of-helsinki-with-enhanced-focus-on-research-ethics-and-inclusion 2024-10-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wma-updates-declaration-of-helsinki-with-enhanced-focus-on-research-ethics-and-inclusion 2024-10-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be-cool-the-briefing-for-18-october-2024-global-competition-review 2024-10-19T04:54:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/be-cool-the-briefing-for-18-october-2024-global-competition-review 2024-10-19T04:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2a-of-cmtx-101-clinical-trial-for-cf-lung-infections-starts 2024-10-19T04:52:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2a-of-cmtx-101-clinical-trial-for-cf-lung-infections-starts 2024-10-19T04:52:06+00:00 weekly 0.7 https://trial.medpath.com/news/optimal-timing-for-video-assisted-thoracic-surgery-decortication-for-improved-survival-in 2024-10-19T04:18:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimal-timing-for-video-assisted-thoracic-surgery-decortication-for-improved-survival-in 2024-10-19T04:18:12+00:00 weekly 0.7 https://trial.medpath.com/news/managing-medication-overuse-headache-in-chronic-migraine-drug-topics 2024-10-19T04:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-medication-overuse-headache-in-chronic-migraine-drug-topics 2024-10-19T04:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/new-atezolizumab-formulation-for-subcutaneous-injection-research-aacr 2024-10-19T03:48:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-atezolizumab-formulation-for-subcutaneous-injection-research-aacr 2024-10-19T03:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-drug-tied-to-vision-loss-study-suggests-becker-s-hospital-review 2024-10-19T03:42:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-drug-tied-to-vision-loss-study-suggests-becker-s-hospital-review 2024-10-19T03:42:26+00:00 weekly 0.7